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ABSTRACT 
Background. Oropharyngeal squamous cell carcinoma (OSCC), where tonsillar and base of 
tongue cancer (TSCC and BOTSCC) dominate, is associated with smoking and alcohol as 
well as human papillomavirus (HPV) infection. The incidence of TSCC and BOTSCC, has 
increased lately, mainly due to HPV infection. In addition, patients with HPV-positive TSCC 
and BOTSCC have a better clinical outcome compared to those with the corresponding HPV-
negative tumors (80% vs. 40% 5 year disease free survival (DFS)). Recently, head and neck 
cancer treatment has been intensified with chemotherapy and more intensive radiotherapy. 
This is likely unnecessary for 80% of HPV-positive TSCC and BOTSCC patients.  
 
Aims. Due to the increase in TSCC and BOTSCC, we wanted to follow oral HPV-prevalence 
in healthy sexually active youth as well as in patients with TSCC and BOTSCC. This in order 
to disclose e.g. whether there were specific traits of oral HPV infection in the latter group. In 
addition, the presence of different HPV16 E6 variants in TSCC were analyzed as well as new 
biomarkers, which could aid in the identification of patients with HPV positive TSCC and 
BOTSCC that could be eligible for de-escalated treatment. 
 
Result. In Paper I we showed that oral HPV prevalence was 9.3% among youth attending a 
youth clinic in Stockholm. Oral HPV infection was more common in women with genital 
infection and there was also HPV-type concordance between the oral and cervical sites. 
When testing samples from patients with suspected HNSCC in Paper II, nearly all HPVDNA+ 
oral samples were derived from patients with HPVDNA+ TSCC and BOTSCC. For healthy 
subjects with oral HPVDNA+ infection, the relative viral load was very low. In Paper III we 
found that the HPV16E6 L83V variant was common in TSCC, cervical cancer (CC) and 
cervical samples (CS), while the rare HPV16E6 R10G variant was present in a proportion of 
TSCC, but absent in CC and only sporadic in CS samples. Neither L83V nor R10G had any 
significant impact on clinical outcome. In paper IV, high number of CD8+ tumor infiltrating 
lymphocytes (TILs) was correlated to a better clinical outcome, especially for patients with 
HPVDNA+ and HPVDNA+ /p16 positive TSCC and BOTSCC. CD4+ TIL counts were not linked 
to clinical outcome or survival for patients with HPVDNA+ tumors, although there was a 
tendency of better survival for patients with HPVDNA- and HPVDNA-/p16-negative tumors. 
Finally in Paper V, patients with HPVDNA+ TSCC and BOTSCC and absent/weak as 
compared to medium/ strong CD44 intensity staining had a significantly better 3-year DFS 
and overall survival. 
 
Conclusion. Oral HPV infection was relatively frequent in Stockholm youth as compared to 
other studies during the same time period, but the relative viral load was in general lower than 
that found for patients with HPV-positive TSCC and BOTSCC. HPV16E6 L83V variant was 
common in TSCC, CC and CS, while the R10G variant was present in a proportion of TSCC, 
but absent in CC and only sporadic in CS samples. Both high CD8+ TIL infiltration and 
absent/weak CD44 intensity staining seemed to be promising predictive markers for patients 
with HPVDNA+ TSCC and BOTSCC.  
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POPULAR SCIENCE SUMMARY 
Populärvetenskaplig sammanfattning 
Cancer i svalget och då framförallt i tonsill och tungbas har ökat i västvärlden sedan 
sjuttiotalet. Riskfaktorer för dessa cancersjukdomar är rökning, alkoholmissbruk och 
infektion med humant papillomvirus (HPV). Cancerpatienter som har HPV i sin tonsill- eller 
tungbascancer svarar lättare på behandling och har en mycket större chans att överleva sin 
sjukdom jämfört med de som har en HPV-negativ cancer. Dagens forskning är till stor del 
inriktad på att förbättra vården för denna patientgrupp samt att utveckla diagnostiska verktyg. 
 
Den här avhandlingen fokuserar på att: 
1. Undersöka HPV i munhålan hos friska ungdomar för att kunna jämföra med HPV 
förekomst hos cancerpatienter 
2. Utvärdera virala och cellulära biomarkörer som diagnosverktyg för att identifiera 
patienter med HPV-positiv tonsill- och tungbascancer med den bästa prognosen, för 
att om möjligt kunna ge dem en mindre aggressiv behandling 
 
Fynd som gjorts är bland annat att 9,3% av friska ungdomar hade HPV i munhålan. I samma 
grupp ungdomar såg man också att infektioner i munhålan var vanligare bland kvinnor med 
en genital HPV infektion. En liknande undersökning gjordes bland patienter med misstänkt 
cancer i munhålan. Bland annat såg vi att patienter med tonsillcancer hade HPV i munhålan i 
~80% av fallen och i allmänhet en större mängd virus i sina prover. 
 
Den vanligaste typen av HPV som orsakar de flesta fallen av livmoderhalscancer, tonsill- och 
tungbascancer är HPV16. Ett HPV16-protein som bidrar till cancerutveckling heter E6. Vi 
har undersökt olika varianter av E6 och bl.a. kunnat visa att en sällsynt variant var vanligare i 
tonsillcancer jämfört med livmoderhalscancer samt i genitala prover från friska kvinnor. 
Ingen skillnad observerades i överlevnad för patienter med denna variant eller andra varianter 
av E6.  
 
Därutöver genomfördes studier av cellulära markörer, i cancerceller och i omkringliggande 
vävnad. Arbetet fokuserade på två olika proteiner, CD8 och CD44. Den förstnämnda 
återfinns på vita blodkroppar som är kända för att bidra till bekämpning av bl.a. virus och 
bakterier. Det andra proteinet har blivit omnämnt som en bidragande faktor i andra 
cancerformer men deltar även i normal cellkommunikation. Studien påvisade att det är 
fördelaktigt för patienter med HPV att ha mycket CD8 men lite CD44.  
 
Resultaten av dessa forskningsprojekt kan i framtiden användas för att bland annat förbättra 
diagnostiken av patienter med tonsill- eller tungbascancer. Ett exempel är fortsatt utveckling 
av vår metod för att testa HPV i munhålan hos cancerpatienter. Denna metod skulle kunna 
användas enkelt och smärtfritt på t.ex. en vårdcentral för att hjälpa vårdgivaren att ge ett 
första besked till en orolig patient. De cellulära markörerna skulle kunna användas för att 
bedöma hur effektiv behandlingen varit och vara till hjälp vid val av behandling. Detta skulle 
kunna optimera patientens välmående i förhållande till cancersjukdomen.  
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1 INTRODUCTION 
 
 
The principle that cancer could be transmissible between organisms was observed already in 
the late 19th century when the Russian veterinarian Nowinsky studied venereal tumors in 
dogs, which were transmissible upon subcutaneous transplantation2. It was however, first in 
1911, that experiments were performed demonstrating that filterable extracts from avian-
sarcomas could transfer a tumor-causing agent from one individual to another. Still it was not 
until later that this phenomenon was proven to be caused by a virus (in this case the Rous 
sarcoma virus).3 
 
Many oncogenic viruses have been discovered since then, and seven of them are known to 
cause cancer in man (Figure 1).4-12 Two of them belong to the Herpesviridae family, namely 
the Epstein-Barr virus4 (EBV) and the Kaposis sarcoma herpesvirus5 (KSHV). EBV has a 
high seroprevalence in the general population (>99%) and may occasionally cause 
lymphomas and nasopharyngeal cancer, whereas KSHV has a much lower population 
seroprevalence (2% - 57%) and usually cases skin tumors and in some instances primary 
effusion lymphoma.6 
 
Human papillomavirus7, 8 (HPV) and Merkel cell polyomavirus9, 10(MCPyV) are two other 
human tumor viruses causing neoplasms of the skin/mucosa. Seroprevalence for both these 
viruses is quite high, between 50-95%. However MCPyV is a rare cause of human cancer, 
while the HPV family contributes to >500.00 cases a year. 
 
Furthermore, there are two human tumor viruses, which are known contributors to 
hepatocellular carcinoma, the Hepatitis B virus and the Hepatitis C virus.11 Even though their 
names imply a family relation, they do belong to different virus families (Hepadnaviridae 
and Flaviviridae respectively) and Hepatitis C virus has in addition been suggested to cause 
some lymphomas.  
 
The human T-lymphotropic virus type 1 (HTLV-1) is another virus known to cause liquid 
malignancy, in this case adult T-cell leukemia, where irregularly shaped lymphocytes 
(leukemic cells) are observed in abundance.12 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Timeline of the discovery of human tumor viruses. Adapted from Moore et al 20103 
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The process by which a infectious agent (may it be a bacteria, virus or parasite) can cause 
cancer varies greatly and it is therefore helpful to divide these into two major categories; 
direct and indirect carcinogenesis.3 Indirect carcinogenesis has been described as chronic 
inflammation created by the agent, ultimately leading to mutations in the host cells.  
Direct carcinogenesis on the other hand, is induced either upon interaction between 
viral/bacterial proteins and the host’s cellular defense, or in the case of viruses e.g. by 
integration of the viral genome in the host genome itself.  Examples of human tumor viruses 
utilizing direct carcinogenesis are HPV, MCPyV, EBV and KSHV. In the case of HPV, the 
virus genome may integrate into the host genome or persist in an episomal form, allowing its 
oncogenic proteins to be transcribed and hence maintain a transformed cell phenotype. 
 
This thesis work will focus on the exciting world of HPV with regard to its detection in 
cancer, as well as in the oral cavity and the cervix in young and healthy individuals. 
Furthermore, immunological aspects and how one should approach cancer related to this 
virus will also be discussed. 
 
1.1 HUMAN PAPILLOMAVIRUS  
 
1.1.1   History of HPV and cancer 
 
Harald zur Hausen was awarded the Nobel Prize in 2008 for his discovery that carcinoma of 
the uterine cervix (below mentioned as cervical cancer (CC)) is to a large extent caused by 
infection with the human papillomavirus (HPV). But the story begins much earlier than the 
21st century. It was observed already in 1842 in Italy, that married women and prostitutes had 
a higher frequency of cervical cancer compared to nuns and virgins, which lead to a suspicion 
that the disease was somehow caused by sexual contact.8 
 
In the early 1970s, this observation was attributed to herpes simplex virus type 2, but 
extensive studies failed to prove this hypothesis. In 1972, it was suggested and later proven, 
that HPV could cause cancer in epidermadysplacia verruciformis, a skin disease with 
uncontrollable growth of skin warts.13 This opened the door to further investigate HPV in 
other cancers, and in the late 1970´s evidence emerged which supported a causative role of 
HPV in cervical cancer. Finally in 1982, Harald zur Hausen and his colleges managed to 
sequence the genome of HPV6 obtained from biopsies of genital tumors.14 This was followed 
by the isolation of HPV16 DNA in cervical cancer biopsies in 1983.15 
 
Soon after these findings, HPV was associated with several other types of cancer such as 
cancer of the vulva, vagina16, penis and anus17. These observations followed in the early 
1980´s and were achieved mostly by analysis of viral DNA with Southern blotting. Reports 
of HPV in relation to head and neck cancer started to appear at about the same time as these 
findings were published.18 The reason why researchers also evaluated head and neck 
squamous cell carcinoma (HNSCC) in relation to HPV was most of all due to the histological 
similarities between bronchial and laryngeal papillomas/squamous cell carcinomas (SCC´s) 
compared to papilloma and SCC´s of the cervix.19, 20 
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The discovery of HPV and its causative role in cervical cancer was for long followed by 
misbelief, similarly to the discovery of its relation to cancer of the oropharynx, which in the 
beginning was dismissed by many. However, when the International Agency for Research on 
Cancer (IARC) acknowledged HPV as a risk factor for oropharyngeal squamous cell 
carcinoma (OSCC) in 2007 this became more widely recognized.21 
 
Today, a lot of young women (and in some instances also young men) are vaccinated against 
HPV in order to relieve the burden of virus related cervical cancer worldwide. The result of 
these huge vaccination programs will not be detectable for many years to come, but it would 
also be desirable to see a decrease in HPV related head and neck cancer. 
 
 
1.1.2    The viral particle and its genome 
 
HPV belongs to the Papillomaviridae family, which is characterized by non-enveloped small 
sized double stranded circular DNA viruses. The HPV capsid is approximately 55 nm in 
diameter with a genome of ~8000bp. One usually divides the genome into 3 parts: The early 
(E) and the late (L) coding regions, which both encode proteins, and the long control region 
(LCR) or non-coding control region (NCCR) (Figure 2).22, 23 
 
- The early coding region 
The early region includes six open reading frames (E1, E2, E4, E5, E6 and E7) and 
composes more than 50% of the viral genome. A reading frame for E8 can be found 
in HPV31. 
 
- The late coding region 
The late region lies downstream of the early region and encodes two late proteins (L1 
and L2), which together make up the viral capsid.  
 
- The non-coding control region 
The non-coding control region does not have any protein-coding function itself, but 
contains both the origin of replication as well as binding sites for transcription factors, 
thus regulating the transcription of the different genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic illustration of the HPV genome (Illustration by: Nathalie Grün) 
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1.1.3    Classification 
 
 
Even though all HPVs have the same basic layout they do differ in several aspects and are 
divided into different genera, species, types and subtypes based on the relatedness of the L1 
DNA sequence. There are five HPV-genera, which have approximately 10% sequence 
diversity of L1. These genera are named the Alpha-, Beta-, Gamma-, Nu- and Mu- 
papillomavirus (Figure 3). Further on, division into subtypes is based on 2-10% diversity for 
the whole genome, however very few HPV´s are divided this far.24 For some HPV types there 
are also different variants, these are different isolates of the same type with less than 2% 
nucleotide diversity. Finally, the term intratype-variant describes differences in e.g. HPV16 
E6, which has five described intratype-variants: European (E), Asian (As), Asian-American, 
African-1 (Af-1) and African-2 (Af-2).25 Intratype variants have also been reported for 
HPV16E2 e.g. EURE2 and AsE2.26 Intratype-variants are assumed to have different 
molecular and biological features.  
 
More than 150 different types of HPV have been reported until today, of which most result in 
asymptomatic infection.24, 27 Some do on the other hand cause skin warts or in rare instances 
also malignant tumors, 12-18 are at present considered to be oncogenic. Depending on which 
cell surface they infect, one usually refers to the different types as either mucosal or 
cutaneous. The Alpha-papillomaviruses are known to infect mucosal surfaces such as the oral 
cavity and genital epithelium. Whereas the Beta-, Gamma-, Nu- and Mu- are associated with 
infection of cutaneous surfaces.21 
 
Furthermore, division into high risk- (HR) and low risk- (LR) types helps in defining whether 
infection is likely to result in malignant transformation or just a local wart. An infection with 
a LR HPV-type is not likely to cause cancer in the long run, however infection with a HR 
HPV-type might initiate a carcinogenic process. 
 
 
Figure 3. Phylogenetic tree displaying all the known genus of HPV and its different species 
Doorbar 2006 © the Biochemical Society24 
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1.1.4    The viral proteins 
 
HPV cleverly uses its host replication machinery in order to reproduce itself in large 
numbers. A more detailed illustration of the coding potential of HPV16 is presented in Figure 
4. As the virus enters human keratinocytes, the viral genome will be transported to the 
nucleus in order for viral replication to take place. First, early proteins E1, E2 and E4-E7 will 
be transcribed. These proteins will interrupt normal cellular functions and will work in favor 
of increased transcription and genome replication. As infection proceeds, late proteins L1 and 
L2 will be transcribed and form the outer layer (or capsid) of the viral particle. Capsids will 
be loaded with replicated viral genomes, creating the complete virus ready for release from its 
host.24 
 
 
 
 
Figure 4. Schematic illustration of the coding potential of the HPV16 genome. 
Adapted from Zheng et al 200623 
 
 
1.1.4.1   E1 and E2 
The E1 protein is generally expressed at a low level and is only active in an efficient way 
upon interaction with E2. These two proteins together are considered to be the most important 
ones during early infection as they together with cellular DNA form a complex, which 
recruits proteins necessary for replication.24, 28  
 
E2-proteins bind to a palindromic DNA motif in the viral genome (in HPV16 close to the 
origin of replication), where it recruits E1, which then may exert is helicase activity. As E1 
opens up the viral DNA, making it accessible to the cellular replication machinery, other 
cellular factors necessary for replication are recruited. Following this, E2 disassembles, 
enabling E1 to form a double hexameric ring, which mimics the cellular hexameric ring 
structures that normally form at the replication of origin in the host cell.28 E2 may also aid the 
segregation of viral DNA by anchoring replicating episomes to mitotic chromosomes of the 
host.29 
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At low levels of expression E2 can function as an activator of transcription, whereas at high 
levels E2 may displace transcriptional activators and thereby repress oncogene expression 
and e.g. the expression of E6 and E7. This dual capacity is believed to be due to differences 
in the affinity of E2 for its different binding sites, initially inducing its own transcription but 
later on, when E2 levels are high, repressing replication.24 Integration of viral DNA often 
disrupts E2 expression, hence favoring expression of E6 and E7, thereby promoting the 
oncogenic process of HPV. However HPV integration is not always observed in human 
cancer.22 
 
 
1.1.4.2    E4 
E4 is translated from spliced E1∧E4 mRNAs, where the E1 and E4 ORF are fused. 
This protein is mostly synthesized in the late phase of viral replication and associates with the 
cytoskeleton in differentiating keratinocytes and is then assumed to take part in the collapse 
of the cytokeratin filament.30, 31 
 
As kerationocytes differentiate, they develop an insoluble matrix of covalently linked 
proteins which protection from mechanical injury. This protein matrix is refered to as the 
cornified envelope. Cytokeratin collaps induced by E4 is suggested to affect the integrity of 
the cornified envelope of the host cell, aiding the newly formed virions in their escape from 
the cell during productive infection.32 In addition to the just mentioned effects, E4 has the 
ability to relocate cycklinB/Cdk2 complexes from the nucleus to the cytoplasm, thereby 
inducing cell-cycle arrest in the G2-phase.33 
 
 
1.1.4.3    E5 
HPV E5 is a transmembrane protein, localized mainly to the endoplasmatic reticulum (ER) 
and Golgi apparatus. E5 binds vacuolar proton-ATPase on cellular endosomes, ending up in 
disrupted endosomal pH. This change in pH blocks internalization of the epidermal growth 
factor receptor (EGFR). In turn, the blocking of internalization leads to EGFR being recycled 
back to the cell surface, increasing receptor activity and cellular proliferation. However, E5 is 
considered to be an oncoprotein with low transforming capacity.22, 24 
 
Furthermore, binding of E5 to vacuolar proton-ATPase has been observed to block the 
expression of major histocompatibility complex (MHC) class II antigens on human 
keratinocytes, which as mentioned previously are the normal target cells for HPV. However, 
keratinocytes do not usually express MHC class II molecules.  
 
MHC class II expression has on the other hand been readily observed in keratinocytes in skin 
disorders with T-cell infiltration as well as in cell cultures upon IFN-γ stimulation. It has 
therefore been suggested that keratinocytes can work as antigen-presenting cells in a scenario 
where infiltrating T-cells produce IFN-γ, thereby inducing MHC class II expression in order 
to evoke an immune response. As this scenario is speculative, there are several hypotheses as 
to how this process takes place. One suggestion is that E5 binds the C-subunit of vacuolar 
proton-ATPase, thereby decreasing its ability to acidify endocytic compartments. Normal 
acidification would induce maturation of MHC class II molecules, however when 
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acidification and hence maturation of MHC class II molecules is blocked, this will result in 
lower cell surface expression of MHC class II. The process behind this hypothetical scenario 
is still unclear but affords an intriguing explanation to MCH class II dysregulation.34 
 
Effects on MHC class I expression induced by E5 have also been observed by two different 
pathways. Firstly, by the same mechanism as suggested for MHC class II, i.e. by binding of 
vacuolar proton-ATPase. Secondly, by the retention of MHC class I molecules in the Golgi 
apparatus by direct binding to the heavy chain.35 
 
These two MHC dysregulation pathways result in reduced MHC class I and class II 
expression on the cell surface, which in turn lead to lower presentation or viral antigens, 
offering HPV two very effective ways of immune escape. However, deletion of E5 is 
frequent in cervical cancer, indicating that E5 is not necessary for transformation hence 
making the question of E5´s importance even more intriguing. 
 
 
1.1.4.4    E6 
One of the main functions of HR-HPV E6 is considered to be deregulation of the tumor 
suppressor p53 (Figure 5). This is achieved when E6 associated protein (E6AP) forms a 
complex with E6 and binds to p53, leading to its ubiquitination and degradation.36  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The many ways in which E6 can affect its host cell and induce oncogenesis.22 
E6 also targets ADA3, another histone acetyltransferase acetylating p53. However ADA3 is 
not only blocked by E6, but is also targeted for degradation by ubiquitination like p53.  
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Looking at E6 of HR- and LR-HPVs it has been observed that they do differ. Although they 
both bind to p53, only binding by HR-HPV E6 results in p53 degradation. The reason for this 
is still unclear, but it has been suggested that HR-HPV E6 can bind at two locations whereas 
LR-HPV E6 only binds to one, thereby only retaining the protein in the cytoplasm. 
Nevertheless, both HR- and LR-HPV E6 can bind directly to the p53 gene and block its 
transcription. Another way in which E6 can affect p53 is by preventing its acetylation and 
hence block stabilization of the p53 protein. This is achieved by binding of E6 to histone 
acetyltransferases p300 and CBP (CREB-binding protein), which would normally acetylate 
p53 and hence activate it.22 
 
E6 also binds to proteins containing a PDZ-domain, inducing degradation of the same, 
thereby contributing to deregulation of cellular adhesion, proliferation and chromosomal 
integrity. E6 can also induce telomerase activity, affect interferon signaling by blocking of 
interferon regulatory factor 3 (IRF3) and mediate degradation of pro-apoptotic proteins (such 
as BAK, BAX), all contributing to further oncogenesis.22, 37 
 
 
 
1.1.4.5   E7 
E7, more specifically HR-HPV E7, is best known for its capacity to bind and destabilize the 
tumor suppressors pRb, p107 and p130. All three are related and regulated by E2F-family 
members (Figure 6). Binding of E7 to pRb disrupts formation of the pRb-E2F complex, and 
this in turn releases E2F. This release will contributes to activation of other cellular effects 
such as G1/S-checkpoint dysregulation and cyclin A and E activation.38  
 
Similarly to the binding difference of HR- and LR-HPV E6 to p53, a difference in the pRb 
binding domain has been observed between LR- and HR-HPV E7, increasing the binding 
affinity to pRB for the latter.37   
 
In addition, E7 has the ability to block the effects CDK-inhibitors (cyclin dependent kinase-
inhibitors) p21 and p27 and induce chromosomal instability.39 E7 also exhibits an immune 
modulating capacity. This capacity is initiated as E7 binds to the interferon regulatory factor 
9 (IRF-9), which is involved in the signaling pathway of interferon-α (IFN- α), and by 
blocking the nuclear translocation of IRF-9, it hence indirectly blocks the antiviral function of 
IFN- α.40 Furthermore, it has been proposed that E7 may block activation of the IFN-β 
promoter by inhibiting IRF-1 signaling.41 This might be exerted as E7 can act directly on 
IFN-γ, suppressing its activation of IRF-1 and hence negatively affect MHC class I 
presentation and IFN-β activation.42 
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Figure 6.  Cellular processes affected by E722 
The most well-known effect of E7 is blocking of the retinoblastoma protein (pRb) which 
allows constitutive activation of E2F. This function among others has a great impact on many 
cellular processes inducing hyperproliferation and S-phase entry. 
 
 
1.1.4.6   Associations between E6, E7, p53, pRb and p16 overexpression  
E6 and E7 are the regulatory proteins that are the most important for the development of HPV 
induced cancer. These two proteins complement each other in the transformation process and 
are highly efficient in immortalizing human primary keratinocytes.37 As described above E6 
acts on p53, while E7 targets Rb, and their effects are thus synergistic. Expression of E7 
followed by inactivation of pRB induces an increase in the levels of p53. This increase is 
however counteracted by E6 as it abrogates p53 induced growth arrest, allowing uncontrolled 
cell growth.  
 
This rescue of one protein effect by the other goes two ways. As mentioned above, binding 
by E7 to pRb followed by disruption of pRb-E2F result in increased expression of the cyclin 
dependent kinase inhibitor p16INK4a (p16).  In the past p16 overexpression was regarded as a 
surrogate marker for active HPV infection, due to this activation.  
 
Following this increase in p16, the effect of E6 can be impaired.39 This effect is however 
counteracted by E7, as it activates cyclin A and cyclin E directly, resulting in bypass of cell 
cycle checkpoints and hence continuous cell division.43  
 
 
1.1.4.7    E3 and E8 – where did they go?  
At present, the E3 gene has only been observed in a few papillomaviruses and has not been 
proven to encode any protein or serve any function.44 
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Most HPV types do not express the E8 protein. When present, the protein is translated from a 
spliced E8∧E2 transcript, where the E8 ORF is linked to the splice acceptor in the E2 gene. 
The transcript has been described for some α-HPVs (HPV5, 1, 11, 16, 18, 31 and 33), but 
not for any β-HPV. The E8∧E2 protein works as a negative regulator of viral replication, 
and downregulates gene expression by working as a repressor of the full length E2, by 
doing so inhibiting E2 repression of E6 and E7 and promoting oncogenesis.45, 46 
 
 
1.1.4.8      L1 and L2 
L1 and L2 are the two capsid proteins, expressed by HPV in the late stages of the virus life 
cycle. The genes encoding these two proteins make up approximately 40% of the virus 
genome. Together L1 and L2 create the viral capsid within which the viral genome will be 
contained. Notable is that expression of the minor capsid protein L2 precedes that of the 
major capsid protein L1.     
 
The way in which genome amplification and capsid protein synthesis are linked is not fully 
understood. This process is assumed to be regulated both at the protein level and by RNA 
processing. E2 is suggested to play a key role in the initiation of late transcription as it 
mediates expression of these genes via splice site usage, creating transcripts that end at the 
late polyadenylation site, generating mRNAs encoding L1 and L2. This is different from the 
strategy for expression of the early genes that are transcribed upon promoter activation and 
not by blocking of polyadenylation.47-49 
 
 
1.1.4.9    LCR 
Transcription of all the viral proteins encoded in the HPV genome is regulated by elements 
located in the long control region (LCR), which contains binding sites for transcription 
factors, silencers and repressors. All of these regulatory elements are borrowed from the host 
cell replication machinery.50, 51  
 
 
 
1.1.5     Life cycle – viral entry, replication, assembly and release 
 
The replication life cycle of HPV is best known in keratinocytes undergoing differentiation 
(Figure 7.). The virus infects epidermal or epithelial surfaces and replicates upon cellular 
differentiation. Viral gene expression then goes through different stages as the cells mature. 
Early genes are expressed in the lower parts of the epidermis, in the basal compartments, 
whereas expression of viral DNA and capsid proteins takes place in the suprabasal part. Viral 
assembly takes place in terminally differentiated cells. 
 
Infection with HPV does not normally cause cancer. However, when viral oncogene 
transcription takes place, disturbing normal cellular activity in combination with e.g. lack of 
immune recognition by the host cancer development may occur.3 Moreover, upon viral 
integration transcription of viral oncogenes can be enhanced and functional mutations may 
also occur.37, 39  
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1.1.5.1   Viral entry 
In most cases HPV enters the body via a small wound in the skin or mucosa of the host, 
gaining direct access to its target cells. Stratified squamous epithelium is the preferred entry 
point for HPV, but cell junctions between different types of epithelial cells such as those in 
the cervix uteri are also targeted. HPV firstly bind to heparin sulfate proteoglycan (HSPG) -
receptors on the epithelial cell surface or on the basement membrane. Binding to the 
extracellular matrix (ECM) is another way in which HPV can facilitate cellular attachment. 
When binding has been established, conformational changes of the capsid and proteolytic 
cleaving of L2 occurs followed by endocytosis. This process is suggested to be independent 
from clathrin-, caveolin-, lipid raft-, flotillin-, cholesterol-, and dynamin-independent.47, 52 
 
 
1.1.5.2    Intracellular transport  
As acidification of the endosome takes place, the virion is disrupted revealing an L2-viral 
DNA complex. This complex is transported by actin protrusions, delivering its cargo to the 
trans-Golgi network, where the final nuclear transport is believed to take place via 
microtubules. The process of nuclear entry is not yet fully understood, but recent research 
indicates that mitosis is necessary, since the breakdown of the nuclear envelope facilitates 
viral-DNA to associate with chromatin. L2 is assumed to mediate this association since it is 
the only molecule following the viral-DNA into the nucleus. However, this is also still 
unclear.  
 
 
1.1.5.3    Replication 
After entry into the nucleus the genome is stabilized as an episome, from which initial 
replication and transcription will occur. Transcription is initiated from the early promoter and 
occurs only from one strand of DNA. As mentioned previously, E2 binds to the viral genome 
and recruits E1, which then opens up the viral DNA for transcription. A majority of the HPV 
genome transcripts are polycistronic. Hence the pre-mRNAs generated will be spliced into 
smaller mRNA pieces encoding different viral proteins. Protein translation takes place in the 
cytoplasm, by the use of the protein machinery of the host cell. 
 
During early infection, all the early viral proteins (E1, E2, and E4-E7) are expressed. These 
proteins enhance cell cycle progression, repress cellular defense mechanisms and block tumor 
suppressors in order for the virus to replicate freely. The late proteins are transcribed as the 
early polyadenylation site becomes blocked by E2, allowing for longer readouts of the viral 
genome, finishing at the late polyadenylation site and thereby generate late mRNAs.  
 
 
1.1.5.4   Assembly and release 
As transcription of the late proteins begin, E2 associates with the viral DNA and recruits L2 
to the nucleus. After translocation, L2 binds to nuclear sub-compartments so-called PML 
bodies in an E2 dependent manner. The function of PML-bodies is not fully elucidated but it 
is assumed that E6 can abrogate PML induced cellular senescence an also directs its 
degradation.37 Notably, PML (promyelocytic leukemia-bodies are found in abundance in 
patients with acute promyelocytic leukemia (APL).53  
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Figure 7. Life cycle – viral entry, replication, assembly and release 
Initially, L1 remains in the cytoplasm and forms capsomers. Only upon L2 binding and PML 
component displacement, will L1 relocate to the nucleus in order to form viral capsids.54 
When the complete viral particle has been formed, further maturation and transport to the cell 
membrane will start.55 As the now finished virus reaches the host cells outer barrier, E4 will 
aid in disrupting the keratin networks and open up the cornified membrane. 
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1.1.6   HPV detection methods 
 
Since HPV was first discovered in skin and mucosal lesions, the most common way of 
sampling has been to collect specimens from these sites. However, the most effective way of 
doing so has been a subject of debate ever since the discovery of HPV. Regardless if actual 
biopsy pieces or cotton swabs from the site of interest are analyzed, the quality of the sample 
and the information extracted from it has always been a matter of discussion. 
 
 
1.1.6.1   Southern blotting 
This method was for long used as a standard method for detection of HPV DNA, but has 
been replaced by PCR during recent years due to the higher sensitivity of the latter method. 
Even so, Southern blots can identify as little as 0.1 copies of viral DNA per cell and the 
difference between episomal and integrated DNA can easily be detected on an agarose gel. In 
a Southern blot, the DNA sample is extracted and cleaved into smaller pieces by restriction 
enzymes, which enables size separation on an agarose gel. The size separated DNA pieces are 
then transferred onto a nitrocellulose membrane and hybridized with isotope-labeled (HPV 
specific probes) which can then be detected.56 
 
 
1.1.6.2   Polymerase chain reaction (PCR) 
PCR is used for direct amplification of HPV DNA and is considered to be very sensitive. 
Primers used for amplification are often general/consensus primers detecting many different 
HPV types but with varying binding/detection sensitivity.  
 
Examples of general primer pairs are GP5/GP6, MY09/MY11 and SPF primers, which all 
bind to the L1-region.57-59In order to overcome the lower specificity for some HPV types due 
to mismatches between the primers and viral sequence, the annealing temperature during the 
PCR is usually lowered. The GP5/GP6 primer sequence can also be modified, such as 
extending them with 3nt, as in the Gp5+/Gp6+ primers.60 This system enables detection of 
HPV types, which previously have been hard to identify in multiplex setting. An alternative is 
to use a mixture of different variant Gp5/Gp6 primers as described for the bead-based 
multiplex assay below.61 Another example of general primers are CPI/CDIIG, amplifying the 
E1-region.62 
 
After amplification, in order to verify presence of viral DNA, the most common method used 
previously was gel electrophoresis, where amplicons were separated depending on size. 
However, when general primers are used the different types HPV cannot be discriminated 
and for this, complementary type specific PCR or sequencing is needed.56 
 
An alternative way to directly identify the HPV type is to use a probe based method such as 
InnoLiPa, which detects multiple types displaying HPV presence by color changes on a 
strip.63  Another, recent approach, is the use of a bead-based assay, which allows multiplex 
type-specific detection by the use of specific probes attached to beads (as described below in 
section 3.3.2). 
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1.1.6.3    In situ hybridization (ISH) 
With ISH e.g. a biotinylated probe (alternatively also labeled with fluorochromes or 
radiolabels) is first hybridized to the viral DNA, where after the signal from the probe can be 
detected and amplified depending on the detection molecules. Presence and localization of 
the DNA can then be evaluated by e.g. light or fluorescence microscopy.56 
 
 
1.1.6.4    Detection of serum antibodies  
As the immune system fights against an HPV infection, B-cells start to produce antibodies 
(Ab) against the capsid protein L1. This happens in ~50% of infected individuals.64, 65 Since 
anti-L1 antibodies are common they are not very useful as diagnostic tool or as a sign of 
tumourigenesis, but can instead be regarded as a indication of a past or present HPV 
infection.66   
 
Ab responses to E6 and E7 are not very common. In addition, recent studies have confirmed 
that presence of Ab against HR-HPV E6/E7 in sera is of note. These Ab may also have 
diagnostic value in both cervical cancer and OSCC, especially for OSCC, where antibodies 
have been observed as early as 10 years before diagnosis.67, 68 Previous studies have often 
focused on HPV status determination upon discovery of a tumor, but the opportunity to early 
on determine serological status as a risk factor in cancer formation is a relatively new 
approach.69 
 
 
1.1.6.5   Immunohistochemistry for viral proteins 
IHC for viral proteins such as E6 and E7 has been performed, however with low success rate 
due to poor sensitivity and specificity, which has led to that this method is not used for 
routine testing. However, recent studies investigating the possible use of E7 staining in 
cervical cancer have shown promising results discriminating between high- and low-grade 
neoplasia. To confirm these findings, further investigations need to be performed, especially 
in relation to HNSCC.70 
 
 
1.1.6.6   Immunohistochemistry for p16 
In the past overexpression of p16 was considered to be a reliable pseudo-marker for active 
high risk HPV infection, with functional E7 protein.71 However, IHC for p16 is not really a 
detection method for HPV. Today this method is routinely used to assess p16 expression 
levels, but the role of p16 overexpression has become more nuanced.  
 
In cervical cancer, upregulation of p16 has been found to be a marker of clinical outcome, 
predicting risk of progression from low grade CIN to higher grades. The same clear 
correlation has not been observed in the case HNSCC and OSCC, although p16-positivity is 
very commonly observed in correlation with infection with HR-HPV.72  
 
In addition, the combination of p16 overexpression together with presence of HR-HPV DNA 
in e.g. OSCC is regarded as almost as sensitive as detecting HR-HPV mRNA.73 
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1.1.7   HPV prevalence in normal population 
 
HPV is one of the most common sexually transmitted diseases in the world. It has been 
estimated that ~70% of the sexually active population will be infected with HPV during their 
lifetime.74 For most of these individuals, an HPV infection will be cleared by the immune 
system within <2 years (with a median of approximately 10 months).75 However, for women 
with persistent infection with HR-HPV, the risk of developing cervical cancer increases 
drastically.76 
 
 
1.1.7.1    Genital HPV infection 
Infection is common for both men and women, but the time point/duration of initial infection 
seems to differ. It has been observed that women have a peak in infection rate in their early 
20´s, as many become sexually active and may have multiple partners. In some studies a 
second peak has been observed at the age of 45-50 years of age, the reason for this is not fully 
elucidated, but it is likely caused by changes in sexual behavior or maybe hormonal changes 
pre-menopause.77 In the male population, a more even distribution of infection throughout 
life has been noted; after an initial peak a more steady prevalence has been observed.77-79 This 
is assumed to derive from more frequent reinfections, as compared to females, although this 
is highly speculative.77 
 
To estimate the actual prevalence in healthy individuals has proven tricky and rates vary 
widely between different studies, sampling techniques and the sensitivity of the assay used. A 
meta-analysis produced in 2010, combining 194 studies performed in 59 countries, suggests a 
world prevalence of 7.2% (11.7% adjusted) in healthy women with normal cytology. 
However the country specific prevalence varied between 1.6% and 41.9% with the greatest 
numbers (adjusted) found in the Caribbean (35.4%), Eastern Africa (33.6%) and Eastern 
Europe (21.4%). In contrast, the lowest prevalence was found to be 1.7% in Western Asia 
and 4.7% in Northern America.80 In the very same study, one could observe that women with 
a mean age below 25 years had a much higher HPV-prevalence compared to other age 
groups. The prevalence then decreased with increasing age until a mean age of ≥55 years was 
reached, then the prevalence increased again.80  
 
This pattern of higher prevalence among younger women has been observed in other studies 
as well. A study performed at a youth clinic in Stockholm, Sweden, found a cervical HPV 
prevalence of 60-70% if including both HR and LR HPV types in young women aged 15-23 
years of age.81 However, it is now well established that; In general cervical HPV prevalence 
usually decreases after 30 years of age, and continues to do so as women approach their 50´s, 
where the prevalence again increases slightly.80, 82 
 
 
1.1.7.2    Anal HPV prevalence 
There is a clear difference in anal HPV-prevalence between men and women. The highest 
prevalence has been observed in men who have sex with men (≥50%, depending on 
population), followed by women who have sex with men (~30%) and finally men who have 
sex with women (~12%, almost half compared to women) according to a newly published 
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report by EUROGIN 2014.83 Other studies report similar prevalence of anal HPV for both 
heterosexual and homosexual men in the age span of 18 to ≥45 years of age.84, 85 It has also 
been reported that homosexual men have a similar prevalence over a wide age span, however 
the study population might suffer selection bias.86 In relation, anal HPV prevalence in women 
has been observed to decrease with increasing age.83 
 
 
1.1.7.3    Oral HPV prevalence 
Oral HPV-prevalence has not been as well studied as compared to genital and anal infection, 
but some trends have however been observed. Men have higher oral-prevalence compared to 
women in some studies.83 This could be due to that females in general have both a higher 
genital prevalence and higher genital viral load as compared to men. Thus the latter are more 
likely to get infected upon oral sex than women.87 Data also indicate that longtime 
monogamous relationships protect men from both genital and oral re-infection by HPV.88 
Other contributing factors could be that men usually have more sexual partners (hence greater 
exposure) and that women might have some level of systemic immunity already present due 
to previous cervical infection, making them more resistant to oral infection.79 It has been 
estimated that approximately 1% of healthy individuals have an oral HPV infection.89, 90 
However, as mentioned above, the numbers of studies on oral HPV prevalence are limited. 
 
One aim of this thesis was therefore to investigate oral HPV prevalence in youth. 
 
 
1.1.8    HPV associated tumors  
 
Tumors harboring HPV can, depending on HPV type, be benign, e.g. skin warts, genital 
condyloma and recurrent laryngeal papillomas. They can also be malignant e.g. cancer of the 
cervix, the anogenital tract or the oropharynx. In this chapter, we focus only on malignant 
tumors (Table 1).  
 
Since the 1980`s, HPV has been accepted as a contributor of cervical cancer. This made 
associations witch other anogenital cancers easier to accept. The association of HPV to 
tumors in the head neck region was on the other hand doubted for a much longer time. Finally 
in 2007, the International Agency for Research on Cancer (IARC) acknowledged HPV16 as a 
risk factor for OSCC, in addition to smoking and alcohol.21  
 
HPV was originally assumed to cause laryngeal cancer, since HPV caused recurrent 
papillomatosis of the larynx.19, 91, 92 However, when investigating different tumor sites in the 
oral cavity in order to find were HPV was most common, it was observed that HPV was most 
frequent in OSCC, especially in tonsillar and base of tongue cancer. The most prevalent type 
was HPV16, representing ~90% of the cases.93, 94  
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Table 1. HPV associated cancer prevalence worldwide, data and estimated percentage of 
HPV positive tumors83, 95-100 
 
Cancer type 
Prevalence, 
Worldwide 
HPV attributable fraction 
Cervical cancer 530.000 >95% 
Head and neck cancer 
-- OSCC 
563.826 
85.000 
~25% 
12-80% 
Vulvar cancer 
40.000 
~40% 
Vaginal cancer 70% 
Penile cancer 26.300 50% 
Anal cancer 30.000 88-90% 
Total  610.000 5% of all cancer 
 
 
1.1.8.2    Cervical cancer and HPV 
Worldwide, cervical cancer is the third most common cancer type affecting ~530.000 women 
every year, being responsible for about 266.000 cancer related deaths/year. The IARC 
classified HPV16 and HPV18 as carcinogenic for cervical cancer in 1995 and it has since 
then been proven that HPV is strongly associated to cervical cancer and pre-cancers of this 
site.101 As mentioned previously, most HPV infections are recognized by the immune system 
and heal in <2 years.75 Only 10-30% of the infections remain detectable for more than 1 - 2 
years. However, in the case of persistent infection with a HR-HPV type (such as 16 or 18) the 
risk of developing cervical cancer increases drastically. More than 90% of all cervical cancer 
cases are related to an HPV infection and the most common types causing the disease are 
HPV16 and HPV18, together being responsible for ~70% of the cases. An HPV infection can 
cause both squamous cell carcinoma (SCC) and adenocarcinoma (ADC) even though SCC is 
more common. 
 
 
1.1.8.3    Anal cancer and HPV 
The prevalence of anal cancer has been estimated to ~1 in 100.000 in the general population 
(with a slightly higher incidence for women) generating about 30.000 cases a year 
worldwide. Out of these, 90% are assumed to be caused by HPV, with an even distribution 
among male and female cases.77, 83, 85 However, when it comes to studies of anal HPV-
prevalence, there has been a focus on studies with male subjects, often homosexual, even 
though the prevalence of anal cancer among females is slightly higher.96  
 
 18 
1.1.8.4    Penile cancer and HPV 
The prevalence for penile cancer is very similar to that of anal cancer with ~1 in 100.000, 
where the fraction contributed by HPV has been estimated to be about 50%. 83, 97  
 
 
1.1.8.5    Head and neck squamous cell carcinoma (HNSCC) and HPV 
Head and neck carcinoma is the sixth most common cancer in the world, representing almost 
3.5% of all tumors. Ninety percent of these are head and neck squamous cell carcinoma 
(HNSCC), most of which arise in the oropharynx, hypopharynx, larynx or in the oral cavity. 
The 5-year survival rate has been estimated to <50%, providing patients with a very poor 
prognosis.102 The prevalence of HPV in HNSCC varies, but has been documented to be 
highest in OSCC.103 Furthermore, in many Western countries the incidence of HPV-positive 
OSCC, especially in tonsillar and base of tongue cancer (TSCC and BOTSCC) has 
increased.104 This has not been shown for other HNSCC, where the prevalence of HPV has 
been reported to be around 22% or less.105 Moreover, the numbers of HPV-positive tumors in 
non-oropharyngeal HNSCC have not been observed to increase. 105, 106 
 
 
1.2 OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OSCC) 
 
Out of the 600.000 possibly HPV associated cancer cases diagnosed each year 10% are 
OSCC and more than three quarters of these are diagnosed in men.107 Risk factors, which 
contribute to disease progression in OSCC, include smoking, alcohol abuse and betel nut 
chewing (common in southeastern Asia).108, 109 In addition, the discovery and 
acknowledgement by the IARC in 2007 that HPV was a contributing factor to OSCC has 
made unprotected sex an additional risk factor. 
 
 
1.2.1   Anatomy of the oropharynx 
The oropharynx is located at the back of the oral cavity, in the middle part of the pharynx, 
and consists of four sub-sites: the palatine tonsils, the base of tongue, the soft palate and the 
walls of the pharynx which are all covered by squamous epithelium (Figure 8). Within this 
area there is a ring of lymphoepithelium often referred to as Waldeyer’s ring, which to some 
extent encircles the oropharynx. This ring includes the lingual tonsils, the palatine tonsils and 
the inferior portion of the nasopharyngeal tonsils (adenoids). The lymphatic epithelium of the 
oral cavity is a squamous cell epithelium, which invaginates and merges with the underlying 
lymphoid tissue, forming crypts, which are often found on the palatine tonsils. There can be 
10-30 crypts/tonsil in the palatine tonsils, while crypts are more rarely found in the tongue 
base, usually only one, and lacking in the nasopharyngeal tonsils.  
 
Due to its specific epithelial structure, tumors arising in the Waldeyer’s ring often metastasize 
early and in the case of very small tumors there will often be neck lymph node metastasis 
discovered prior to an actual find of a primary tumor.93, 110 
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Figure 8. The oropharynx is located in the back of the oral cavity and includes the base  
of tongue, tonsils, soft pallet and pahryngeal walls (not displayed in the picture). 
Ilustration by Nathalie Grün 
 
 
1.2.2    Prevalence of HPV in OSCC  
The prevalence of HNSCC has declined over the last decades in the western world, where 
smoking habits have decreased. However the prevalence of OSCC as a separate group has 
increased. This trend has been reported in many countries such as U.S., Sweden, England, 
Scotland, Australia, Finland, Spain, Canada, Portugal, New Zeeland, the Netherlands and 
Denmark.111-126 Even more intriguing is that HPV-positive OSCC seems to be increasing, 
whereas HPV-negative OSCC has been decreasing as illustrated for TSCC in Stockholm 
Sweden from 1970-2007 (Figure 9).127 Similar data have also been shown for BOTSCC in 
Stockholm, Sweden and OSCC in the U.S.115, 128   
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
Figure 9. Estimated age-standardized incidence for HPV-positive and HPV-negative tonsillar 
squamous cell carcinoma (TSCC), Stockholm Sweden.127 
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The HPV prevalence in OSCC has been reported to vary over geographical regions with 
about 60-70% in the United States, ~40% in Europe and 46% in Asia.97, 105-107 The reason for 
these variations is unknown, but they are assumed to be due to lifestyle differences. HPV 
prevalence may also vary between tumor sites. A meta-analysis from 2014 indicated a 45.3% 
HPV prevalence in tonsillar cancer compared to 39.6% in the pharynx. Notably, HPV16 
dominates excessively in OSCC, whereas other types such as 18, 33, 31 and 35 are found less 
frequently.129  
 
 
1.2.3    OSCC and clinical outcome 
As mentioned briefly above, HPV-positive OSCC, especially HPV-positive TSCC and 
BOTSCC have a better clinical outcome as compared to the corresponding HPV-negative 
cancers (80% vs. 40% respectively 5-year disease free survival) (Figure 10).130 This has been 
found to be the case even with conventional radiotherapy and surgery.131, 132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 10. Survival rates, tonsillar cancer in Sweden132  
 
 
The reason for the discrepancy is not yet known between patients with HPV-positive tumors 
and HPV-negative tumors. It has on the other hand been shown that patients with HPVDNA+ 
tumors who are non-smokers have an even better clinical outcome, and that with each 
package of cigarettes their clinical outcome is worsens. Nevertheless, smokers with HPVDNA- 
OSCC have the poorest clinical outcome.133  
 
 
 
 
 
 
  21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Survival rates, base of tongue cancer in Stockholm, Sweden. 131 
 
 
 
1.2.4    Treatment for HNSSC and OSCC 
Early stage HNSCC is treated with either surgery or radiotherapy, often with good results. 
Unfortunately, these patients only represent one third of all cases. More advanced disease is 
usually treated with surgery, in combination with radiotherapy. In some cases chemotherapy 
with platinum based compunds is also need. Cetuximab (also Erbitux), a monoclonal 
antibody blocking EGFR, has also been used in combination with radiotherapy. This 
combination has in some cases been observed to yield better results than radiotherapy in 
combination with chemotherapy. In the case of metastasis or recurrent disease, different 
chemotherapy combinations and salvage surgery are often the only options. Cisplatin in 
combination with 5-fluorouracil (5-FU) is commonly used. However, even with all these 
treatment options, the prognosis is poor.134 
  
Due to this documented poor prognosis of HNSCC, treatment of all HNSCC including OSCC 
has been intensified the past decade with induction or concomittant chemotherapy, 
hyperfractionated radiotherapy, and in some cases Cetuximab. This treatment has lead to 
many more serious acute and chronic side effects, such as difficulties to eat, speak and breath 
and in many cases the patients have not been able to go back to an ordinary working life. In 
addition, treatment has been prolonged and the costs for society have increased.135 
 
It is also very doubtful if the majority of patients with HPVDNA+ OSCC need intensified 
treatment. However, since not all patients survive with standard radiotherapy, it is important 
to identify patients that will respond to therapy. Here, together with an HPVDNA+ or combined 
HPVDNA+/p16 positive tumour status, additional biomarkers maybe of use to better identify 
patients that will respond to therapy.  
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1.2.5.    Biomarkers for prognosis in OSCC and HNSCC 
 
Besides the presence of HPV, the roles of different biomarkers have been examined for their 
influence on clinical outcome in HNSCC and OSCC. Well known examples are such as the 
presence of p16, mutated p53 and other immunological markers such as MHC expression or 
tumor infiltrating lymphocytes.136-139  
 
In many studies HNSCC from different sites have been analyzed together and thus the 
specific location of the tumor not been taken into account. In addition, the HPV status of the 
tumors has often not been analyzed. It is now recognized that e.g. HPV-positive and HPV-
negative OSCC should be considered as two different tumor entities and it is therefore crucial 
to define the HPV status of the tumors in studies of biomarkers for prognosis.130-132 The fact 
that the level of HPV infection differs between the different sites adds an extra dimension to 
this relation since e.g. HPV is very common in TSCC and BOTSCC, but almost absent in 
cancer of the hypopharynx.105, 115 
 
In this thesis we have focused on 3 different biomarkers in relation to prognosis CD4, CD8 
and CD44. 
 
CD8+ and CD4+ tumor infiltrating lymphocytes (TILs) are recognized as prognostic markers 
and have been studied in a number of cancer forms such as breast cancer, lung cancer and 
prostate cancer140-143 
 
In these cases, numbers of CD4+ TILs have been both negatively and positively correlated to 
prognosis and numbers of CD8+ TILs have been positively correlated to prognosis.141, 144 
An important function of CD8+ T-cells is to participate in the host defense during infection 
with viruses and intracellular bacteria by killing of infected cells. CD4+ T-cells on the other 
hand activate B-cells which in response will produce antibodies. They also produce cytokines 
which activate other parts of the immune system.145 Lymphocytes expressing either of these 
markers are therefore considered as important with regard to prognosis. Their exact role in 
cancer progression is however not fully elucidated. 
 
The relation between CD44 and prognosis has also been studied in several cancer forms, e.g. 
lung cancer and breast cancer.146, 147 Most of the observations point to a negative correlation 
between CD44 and prognosis.148, 149 CD44 is involved in cell aggregation, proliferation, 
migration and angiogenesis. This cellular receptor has therefore been proposed to induce 
cellular proliferation of malignant cells. Upon binding of hyaluronic acid, crosslinking of 
tyrosine kinase receptors is mediated hence mediating proliferation.150 Therefore, it is 
reasonable to assume that absent/weak CD44 staining contributes to a better clinical outcome. 
 
 
 
To find other biomarkers besides HPV has been one of the additional aims of this thesis. 
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1.3 PREVENTION, SCREENING AND VACCINES 
 
The most effective way to prevent oral and cervical HPV infection is most likely to avoid 
having sexual contact, and as mentioned above cervical cancer was rare in nuns. Also having 
few sexual partners may be associated with a lower oral and genital HPV prevalence.151  
 
It has however been discussed, whether HPV infection can be inhibited by distributing 
contraceptives which will protect against genital and oral infection, such as condoms and 
dental dams.152, 153 There is also a need for information and sexual education in order to 
educate the population on how to protect themselves against the negative factors associated 
with unprotected sex.154, 155 
 
Screening for cervical cancer, introduced by Papanicolaou156, has been proven useful for 
early detection of pre-stages to cervical cancer and although not perfect its use has saved 
millions of lives in the countries where it has been introduced.157 Today screening for HPV 
infection is suggested to be very useful e.g. for women above 35 years of age.158, 159 For 
HPV-positive OSCC there are no implemented screening procedures and there is thus a need 
to evaluate the possibility to screen for HPV-positive OSCC.  
 
Therefore, to investigate the possibility to screen for HPV-positive OSCC has been an aim of 
this thesis. In addition, we studied whether different HPV16 variants were observed at 
different locations and if these variants were linked to clinical outcome. 
 
 
1.3.1    Prophylactic vaccines 
Today, there are two prophylactic HPV vaccines commercially available, Gardasil® 
(GalaxoSmithKline, UK) and Cervarix® (Merck, USA). Both of these protect against 
infection with the two most common HR-HPV types, 16 and 18, covering approximately 
70% of all HPV related cervical cancer. In addition, Gardasil® protects against LR-HPV6 
and 11 which are the most common cause of condylomas.  
 
The prophylactic vaccines are based on so-called virus like particles (VLPs), which are made 
up of the L1 capsid proteins that self-assemble into VLPs. The adjuvant used differs between 
the two vaccines. Cervarix® utilises aluminium hydroxide and is produced in insect cells, 
whereas Gardasil® contains amorphous aluminium hydroxyphospate sulfae an is produced in 
yeast.160 
 
When it comes to immune response and efficacy of the two vaccines,  studies indicate very 
good protection from both vaccines with ~100% prevention of CIN III related to HPV16 and 
18.161 Studies investigating additional protective effects have been performed, indicating 
cross-protection against some other HR-HPV types such as HPV33, 31 and 52.162 Cross 
protection is an important matter, since it may prevent aditional cervical cancers. More 
studies are however needed, since present data indicate varying levels of cross-protection (up 
to 40% in some cases) and also there is the possibility of shorter duration of cross-
protection.163  
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The effector mechanism of both vaccines appear to be similar, since both evoke a clear 
antibody response. However, It is has been suggested that it is unlikely that CD4+ T-cell and 
CD8+ T-cell related effector mechanisms play a major role in prevention of infection. 
Cervarix® has been shown to evoke a more Th1 related response, while Gardasil® evokes a 
more Th2 related response. Moreover, although a strong CD8+ response is induced against 
L1 expressed in the upper layer of differentiated kertainocytes, it is unlikely that these 
lymphocytes come in contact with the HPV infected reproducing cells, and thereby 
erradicating them and curing the infection.164  
 
Regarding the antibody response, it appears as if vaccination provides a much better initial 
response as compared to the antibody response caused by natural infection. A randomized 
placebo-control study from 2004 investigating bivalent vaccination, indicated that antibody 
titers were 100-times higher than those obtained after natural infection and 18 months after 
vaccination they remained up to 16 times higher and seemed to persist over time.165 Also, 
studies of memory B-cells from vaccinated women with no previous immunity towards 
HPV16 have been performed. Observations of HPV16-specific memory B-cells were made, 
however no tests were made of whether these cells gave rise to Abs in serum in this specific 
study.166 
 
There are numerous studies of how efficient the two HPV vaccines are in protecting against 
HPV16 and HPV18 infection in the cervical tract.160-162 However, there are fewer studies on 
the ability of HPV vaccines to protect against oral HPV infection of which the article by 
Herrero et al was one of the first to show that HPV vaccination also reduces oral HPV 
infection.167 
 
 
1.3.2    Therapeutic vaccines 
There are no therapeutic HPV vaccines in use today, although many attempts have been 
made. Therapeutic vaccines generally aim to induce a strong Th1/cytotoxic T-cell response, 
which should be sufficient to clear a tumor driven by HPV antigens. Strategies tested so far 
include recombinant viral vectors and proteins, naked DNA, antigen pulsed dendritic cells 
and HLA-class I restricted peptide epitopes. 
 
Even if one of these vaccination strategies would have induced a strong T-cell response other 
complications may lie ahead. HPV might still utilize some of its immunosuppressive features, 
which might be hard to overcome. Furthermore, mutations arising after the initial infection 
could potentially still drive tumor growth after virus eradication, making such a vaccine less 
useful.168  
 
Two recent studies have reported 50% successful treatment of patients with HPV16 related 
high-grade vulvar lesions. The first vaccine was based on synthetic peptides of HPV16 E6 
and E7 and the second one was based on recombinant HPV16E6E7L2 fusion protein. Both 
these vaccines managed to induce a strong CD4+ T-cell response and induction of CD8+ T-
cells, both specific for HPV16. However these vaccines did not induce tumor regression in 
cervical cancer patients.168 
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2 AIMS 
 
• Investigate the prevalence of HPV in the oral cavity of healthy youth, as well as in 
relation to cervical HPV prevalence 
 
• Investigate oral HPV prevalence and cytology in patients with HPVDNA+ TSCC and 
BOTSCC to examine whether it is possible to find useful screening methods 
 
• Study whether there are different HPV16 variants in HPV-related tumors, compared to 
those in samples from healthy subjects 
 
• Evaluate the influence of HPV-status and other biomarkers in TSCC and BOTSCC in 
response to therapy 
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3 MATERIAL AND METHODS 
 
3.1 STUDY SUBJECTS  
 
Several different cohorts were included in this thesis. Paper I included 490 healthy youth 
attending a youth clinic in central Stockholm, between 2009 and 2011. Paper II included 76 
patients with suspected HNSCC visiting Karolinska University Hospital 2011 until 2013. In 
addition to the patients in Paper II, 37 dental patients attending the dental school at the 
Department of Dental Medicine at Karolinska Institutet were used as controls. Paper III had a 
total of 211 samples, including cervical samples from youth taken 2009-2011, cervical cancer 
biopsies and tonsillar cancer biopsies from patients diagnosed between 2000-2008 at 
Karolinska University Hospital. Papers IV and V included a cohort of almost 300 patients 
diagnosed with TSCC and BOTSCC between 2000 and 2007 at the Karolinska University 
Hospital.  
 
3.2 PATIENT MATERIAL 
 
Several different types of patient samples were used in the projects included in this thesis 
according to the list below.  
 
 
Paper I 
 
Mouthwash samples (50% water, 50% Listerine, totally 15ml) from 408 women and 82 men, 
15-23 years of age, were included in the study. In addition, 180 women contributed with 
cervical samples collected with swabs (made out of nylon) in 5ml SurePathTM. Of these 
women, 174 also contributed with oral samples (included in the total 408). Seven oral samples 
(all from women) were excluded due to lack of genomic DNA in the samples. All samples 
were collected at a youth clinic in central Stockholm between 2009 and 2011. 
 
 
Paper II 
 
Mouthwash samples, with the same formula as in Paper I, were collected from September of 
2011 until June 2013 from 76 patients with suspected HNSCC. Tonsillar swabs from both the 
right and left side were also sampled by a nurse. Patients were recruited when they visited the 
department of ear-nose-throat surgery at Karolinska University Hospital (ENTKS), in order to 
undergo diagnostic endoscopy due to suspicion of HNSCC. In total, 29 TSCC, 18 BOTSCC 
and 19 other HNSCC/benign conditions were identified. In addition, 37 mouthwash samples 
and 24 pairs of tonsillar swabs were collected in 2011 from patients attending the dental 
school at the Department of Dental medicine at Karolinska Institutet. 
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Paper III 
 
Three different sample types were used in this study which were obtained from patients either 
from the Karolinska University Hospital or a youth health center in Stockholm: 
      - 108 TSCC samples from patients diagnosed 2000-2007 
      -   52 Cervical cancer (CC) samples from patients diagnosed 2003-2008 
      -   51 Cervical samples (CS) from women attending a youth health center in Stockholm   
          2009-2011 
 
 
Paper IV 
 
In all, 275 formalin fixed paraffin embedded TSCC and BOTSCC biopsies, obtained from 
patients diagnosed 2000-2007, and earlier tested for HPVDNA and p16INK4a, were stained for 
both CD8+ and CD4+.   
 
 
Paper V 
 
The same initial cohort as in Papers III and IV was used in this project. This time 290 OSCC 
pretreatment biopsies were available for staining of CD44. 
 
 
3.2.1    Ethical permissions 
All studies included in this thesis were performed with permission from the Stockholm 
Regional Ethical Committee. List of permissions as follows: 
 
• Paper I: 2008/870-31/4 and 2009/1147-31/2 
• Paper II: 2009/1278-31/4 and  2010/1758-31/4 
• Paper III: 2005/431-31/4, 2005/1330-32, 2008/870-31/4, 2008/813-31/2 and 
2009/1278-31/4 
• Paper IV: 2005/431-31/4, 2005/1330-32 and 2009/1278-31/4 
• Paper V: 2005/431-31/4, 2005/1330-32, and 2009/1278-31/4 
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3.3 METHODS 
 
 
3.3.1    DNA extraction 
 
Samples and DNA extraction kits 
DNA was extracted from several types of samples, such as e.g. mouthwash samples, tonsillar 
swab and cervical swab samples, and FFPE biopsies from different tumor samples. Three 
different kits were used for the DNA extraction: 
 
• Gentra Puregene Buccal Cell Kit (Qiagen) Adapted to mouthwash samples 
• High pure PCR template preparation kit (Roche) for oral and cervical swabs 
• High-pure RNA paraffin kit (Roche) for FFPE material 
 
 
3.3.1.1     The adapted version of the Gentra Puregene Buccal Cell Kit 
 
The protocol for the Gentra Puregene Buccal Cell Kit was adapted according to sample type 
that was used, since this kit can be used for different sample types and of varying quality. The 
procedure was very much different compared to the other two kits, since filter tubes was not 
used in the protein extraction.  
 
Samples containing a 15ml 50% Listerine/50% water mixture, which had been gargled 30sec 
by the patient, were stored at 4° C for a maximum of three days. The total sample was 
centrifuged and the pellet was washed in PBS. From this step, the pellet was resuspended and 
either extracted immediately, or as in most cases frozen down for extraction later on.  
 
Upon DNA extraction, the pelleted cells were lysed in cell lysis solution, followed by protein 
lysis by Proteinase K. The lysed proteins were then pelleted upon centrifugation after protein 
precipitation solution was added. The supernatant containing DNA was then further processed 
by transfer into a mix of isopropanol and glycogen solution. At this stage the DNA “lumped 
together” and was easily spun down in a centrifuge with a built in cooling system. The pellet 
was then washed in 70% ethanol, air-dried and resuspended in DNA hydration solution, where 
after the DNA concentration was measured. 
 
This kit was chosen for extraction of mouthwash samples, since it has been designed to 
remove enzymes and contaminants in an easy and effective way. Mouthwash samples contain 
proportionally large amounts of saliva, which in turn contains many degrading enzymes. It 
was therefore important to use a procedure, which was specifically designed for this sample 
type. 
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3.3.1.2     The High-pure RNA paraffin kit 
 
The High-pure RNA paraffin kit was used to prepare DNA from FFPE-biopsies. The DNAse 
step was removed from the protocol, hence a mix of both RNA and DNA was obtained. 
Fifteen micrometer thick sections (cut on a microtome at the core facility for histopathology at 
Cancer Center Karolinska) were deparaffinized with xylene and >96% EtOH. Then samples 
were mixed with tissue lysis buffer, 10% SDS, Proteinase K and left to incubate at 56◦C 
overnight. The following day, the samples were treated with binding buffer and moved to a 
filter tube, treated with wash buffer I and II, followed by elution and measurement of DNA 
concentration. 
 
As DNA and RNA in paraffin embedded material is often to some extent degraded, the choice 
of extraction method is of great importance. With this kit one can extract total RNA, but a mix 
of DNA/RNA is also achievable when removing the DNase step. By treatment with DNase or 
RNase pure DNA or RNA can be obtained, which gives the researcher the option of 
flexibility. 
 
 
3.3.1.3    The High pure PCR template preparation kit 
 
The procedure does not differ largely between the High pure PCR template preparation kit 
and the High-pure RNA paraffin kit. Samples were either buccal or cervical cells on swabs 
stored in SurePath™ solution at 4◦C until preparation could begin, which was usually initiated 
within ≤ 3 days. The swabs were then vortexed in their 15ml storage tubes containing 5ml 
SurePath™, where after 1.5ml liquid was removed for further processing. The 1.5 ml samples 
were then mixed with 10mM TrisEDTA-buffer (pH8), tissue lysis buffer and Proteinase K and 
incubated at 55ºC for 1hour. After the initial cell lysis, binding buffer was added followed by 
incubation at 70ºC. Isopropanol was then added and the mix transferred to “High pure filter 
tubes”. The samples were then centrifuged and eluted with 70ºC warm elution buffer and the 
DNA concentration was measured. 
 
This kit is designed more for fresh material as compared to the The High-pure RNA paraffin 
kit. The option of using RNase to obtain pure DNA is available, instead of DNase as in the 
High-pure RNA paraffin kit above. As this procedure includes spin columns based on salt 
gradients, the need of organic solvents and DNA precipitation is eliminated, making it fast and 
easy to use. 
 
 
3.3.2    Conventional and Multiplex PCR for HPV detection 
 
3.3.2.1    Conventional PCR 
In conventional PCR (also called standard PCR) only one target is amplified at the time. 
Although frequently used earlier this was not the main method for most projects included in 
this thesis. Multiplex PCR (described in the next section) replaced the conventional PCR in 
our lab to a large extent, as it offers an easier and more effective way of acquire the same 
information. 
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Conventional PCR had been used to some extent in the analysis of HPV DNA status on 
tumours included in Paper III-V. Samples in these cohorts were first tested by type specific 
PCR for HPV16E6. The type specific PCR was first performed for HPV16, as this is the most 
common type found in OSCC. If the initial analysis was negative, PCR with consensus 
primers followed. First primers GP5+/GP6+ were used, amplifying L1 of most known HPV-
types. If this second test came out negative, the consensus primer pair CPI\CPIIG was used, 
amplifying E1 in case of L1 deletion.62 For samples still negative for HPV DNA, an additional 
PCR analysis for the cellular gene S14 was performed as a positive control for amplifiable 
cellular DNA. In Paper III, conventional PCR was used prior to sequencing of HPV16E6 in 
order to amplify the material of interest. 
 
Example of a PCR protocol layout:                      PCR cycling program: 
 
 
 
 
 3.3.2.2 Multiplex PCR 
 
Multiplex PCR was applied for all samples where HPV status was determined in Paper I and 
Paper II. This was done either for 24 HPV types (as in Paper I) or 27 HPV types (as in Paper 
II). The 24 HPV type PCR amplified the L1-region of HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 
42, 43, 44, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82. The additional types for the 27 
HPV type set up were: HPV30, 67 and 69. These were not prioritized in the original set up 
since they are regarded as HPV types where there is limited or inadequate information 
regarding carcinogenesis.169   
 
HPV16E6 region was also included in the Multiplex 27 HPV type setup, since L1 might be 
deleted in some tumors it was of importance to investigate whether this was the case. HPV16 
is the most common type associated with human cancer and variations of this type is therefore 
of great importance.  
 
The cellular household β-globin gene was also included as a control for presence of genomic 
DNA. For the multiplex PCR reaction the Qiagen Multiplex PCR kit was used. The protocol 
was adapted depending on the type of sample with the total volume of the PCR reaction either 
25µl (for FFPE samples and cervical swabs) or 50µl (in the case of mouth wash samples and 
oral swabs).  
No of  samples: 1 
  10x PCR buffert(PE)    5 µl 
dNTP (1.25mM/dNTP) 8 µl 
MgCl2(25mM) 3 µl 
Primer.F (10pmol/µl) 2 µl 
Primer.R (10pmol/µl) 2 µl 
dH2O 24.8 µl 
Taq pol gold (5U/µl) 0.2 µl 
Sample 5 µl 
    
Total 45 µl 
95°C 4 min  1hold 
  95°C 30 sec 40cycles 
49°C 30 sec 
 72°C 2 min 
 
  72°C 10 min 1hold 
4°C  
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When the multiplex HPV PCR was set up the results were compared to those obtained by 
conventional PCR. Although the agreement was good between the assays we found that the 
multiplex PCR had a higher sensitivity and that less DNA was needed to obtain the same 
results. 
 
Example of PCR layout for 50µl protocol:                     The PCR cycling program: 
 
PCR 
   No of samples 1 ul/sample 
    Primer set 1 HPV (BSGP5+/6+ 
primer set) 
 
2 
Primer set 2 (b-globin primers) 
 
0,5 
P217-HPV16E6-1.F 
 
0,12 
P234-HPV16E6-3.R  
 
0,076 
2xQiagen Multiplex PCR Master Mix 25 
H2O 
  
12,304 
    Total volume 
 
40 
    µl sample 
  
10 
     
 
One primer in each primer pair was biotinylated, so that a detection molecule could be added 
later on. Visualization was performed via a multiplex bead based assay, evaluated on a 
Magpix instrument supplied by Luminex (Figures12.). This instrument allows detection of as 
many as 50 specific targets in a small amount of sample, e.g. 5 ng tumor DNA or 5-10 µl of 
DNA preparation from cervical samples. Since the samples are analyzed in 96-well plates, this 
significantly lowers the workload and processing time of a standard PCR approach. 
 
 
Magpix procedure: 
The PCR products were mixed with a solution containing MagPlex® Microspheres (or beads), 
which are carboxylated polystyrene micro-particles, each with a unique flourescent color.170 
These beads are coupled to HPV specific probes enabeling them to hybridize with  single-
stranded HPV amplicons  upon denaturation at 95ºC, followed by a 30 minute incubation at 
41ºC. Furthermore, a solution containing flourecent streptavidin detection molecules was 
added, followed by further incubation at room temperature. The resulting DNA-bead- 
flourecent streptavidin -complexes were visualized on a MagPix instrument, using two lasers 
(one red visualizing the beads and one green visualizing the detection molecule). Each bead 
has a unique fluorescent color allowing this detection. The amount of flourecent streptavidin 
connected to each bead can also be measured and used as semiquantitative measure of the 
amount of the specific PCR product. 
 
 
 
 
 
94oC 15 min 1 hold 
  
 
94oC 20 sec 40 cycles 
38oC 1 min 30 sec  
71oC 1 min 20 sec  
  
 
71oC 4 min 1 hold 
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Figure 12. Schematic illustration of the bead-complex and illustration of the laser detection 
system used by the MagPix instrument. A red laser enables detection of the beads, whereas a 
green laser detects the detection molecule, e.g. fluorescent streptavidin. 
 
 
The output is recorded in median fluorescent intensity (MFI) and is presented in an Excel 
based matrix displaying the MFI for each sample and individual bead type. In the current 
assay corresponding to different HPV types, all HPV types tested for at the top and all samples 
tested from top to bottom. A negative control is then used to determine the level of 
background noise. In addition, to avoid false positives, a factor of 15 was subtracted from the 
initial MFI output. The cut-off used for a positive sample was: Background*1.5 + 15.    
For sample types that generated mostly very weak results, there was no risk of false positives 
due to weak cross-reactions with other HPV types. In these cases a lower cut-off of was used:  
Background*1.5 + 8. 
 
In addition, a β-globin level with an MFI >30 was considered as an indicator of sufficient 
DNA with a high enough quality for evaluation. This was especially important for HPV 
negative samples since HPVDNA+ samples did not need β-globin to be regarded as positive 
since the PCR obviously worked for the viral DNA. 
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Table 2. Primers included in the Luminex assay 
 
Forward 
Name sequence    gene 
GP5+ 5´-TTT GTT ACT GTG GTA GAT ACT AC-3´   L1 
BSGP5+-2 5´-TTT GTT ACT GTT GTI GAT ACT AC-3´    L1 
BSGP5+-3 5´-TTT GTT ACT GTT GTI GAT ACC AC-3´    L1 
BSGP5+-4 5´-TTT GTT ACT TGT GTI GAT ACT AC-3´    L1 
BSGP5+-5 5´-TTT TTA ACT GTT GTI GAT ACT AC-3´    L1 
BSGP5+-6 5´-TTT GTT ACT GTG GTA GAC ACT AC-3´   L1 
BSGP5+-7 5´-TTT GTT ACA GTI GTA GAC ACT AC-3´    L1 
BSGP5+-8 5´-TTT GTT ACA GTI GTA GAT ACC AC-3´    L1 
BSGP5+-9 5´-TTT GTT ACT GTG GTA GAT ACC AC-3´   L1 
HPV16E6-1.F 5´- TCA AAA GCC ACT GTG TCC TGA -3´  HPV16 E6  
HPV33E6.F       5´-TCG TTG GGC AGG GCG CTG TG-3´                                     HPV33 E6/E7 
MS3.F                5´-AAT ATA TGT GTG CTT ATT TG-3´    β-globin1 
bglobin1170.F  5´-GTA CAC ATA TTG ACC AAA TCA GGG TAA-3´   β-globin1 
 
Reverse (5´ Biotinylated)  
Bio-GP6+ 5´-GAA AAA TAA ACT GTA AAT CAT ATT C-3´   L1 
Bio-GP6+-b 5´-GAA AAA TAA ATT GTA AAT CAT ACT C-3´   L1 
Bio-GP6+-c 5´-GAA AAA TAA ATT GCA ATT CAT ATT C-3´   L1 
HPV16E6-3.R 5´- GCT GGG TTT CTC TAC GTG TTC -3´  HPV16 E6  
HPV33E6.R       5´- CTC GTG TCC TCT CAT GGC GTT-3´                                  HPV 33 E6/E7 
Bio-MS10.R 5´-AGA TTA GGG AAA GTA TTA GA-3´    β-globin1 
bglobin1293.R   5´-GCC CTG AAA GAA AGA GAT TAG GGA AAG-3´   β-globin1 
 
1In earlier studies MS3.F and Bio-MS10.R were used. These were later replaced by 
bglobin1170.F and bglobin1293.R with a higher annealing temperature and giving a shorter 
amplicon. 
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3.3.3    DNA-sequencing on a”Applied Biosystems 3730 DNA analyzer” 
 
PCR-products were cleaned from excess primers and nucleotides by the use of ExoSAP-IT®, 
first heated to 37°C for 15 minutes followed by enzyme deactivation at 80°C for 15 minutes. 
The product is based on a combination of two enzymes Exonuclease I and Shrimp Alkaline 
Phosphatase (SAP). Exonuclease I works by removing the remaining single-stranded primers 
and left over single-stranded DNA, which has been produced during the PCR while SAP on 
the other hand, dephosphorylates residual dNTPs.171 
 
The sequencing PCR was initiated after cleaning of the PCR-product.  For this PCR automated 
dye-terminator sequencing was used. During the sequencing reaction, fluorescent 
dideoxynucleotides (ddNTPS) were incorporated in the DNA, terminating the reaction of the 
very same DNA strand, emitting light at different wavelengths.172, 173 The data was then 
recorded on an Applied Biosystem 3730 DNA analyzer. 
 
Example of sequencing PCR layout and cycling program: 
 
HPV sequencing PCR   PCR-program  
Number of samples 1    
   96oC 10sec 25 cycles 
Big Dye mix   4 µl  50oC 5sec  
2.5 Seq. dilution buffer 2 µl  60oC 4min  
Primer (1pmol/ul) 3 µl    
Template 5 µl    
H2O 6 µl    
     
Total 20 µl    
 
 
 
3.3.4    Immunohistochemistry (IHC) 
 
Immunohistochemistry was used for detection of CD8+ and CD4+ tumor infiltrating T-cells 
and for the expression of CD44 on the tumor cells with the following antibodies: 
 
• CD44 clone:DF1485, Monoclonal mouse anti-human 1:1000 
(Dako, Glostrup, Denmark)  
• Anti-CD8 clone:4B11, Monoclonal mouse antibody 1:40 (Novocastra) 
• Anti-CD4 clone:1F6, Monoclonal mouse antibody 1:40 (Novocastra) 
• p16 Clone:JC8, Monoclonal mouse antibody 1:100 (Santa Cruz Biotechnology, Inc.) 
 
Data from immunological staining of p16 was also used. Most staining and evaluation of this 
protein was performed in a routine setting at the Department of Clinical Pathology at the 
Karolinska University Hospital, Stockholm, Sweden, and if not, this was done by us.   
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Summary of standard protocol for IHC: 
 
Slides were first de-paraffinized in xylene for 5minutes, followed by lowering concentrations 
of ethanol á 5 minutes each (70, 95, 100%). Antigen retrieval was then performed by washing 
the slides, then placing the slides in citrate buffer in a water bath, which was brought to a boil 
in a microwave and then kept just below boiling point for totally 30 minutes. Following this, 
the slides were allowed to cool down and washed. Then blocking of unspecific binding with 
1.5% horse serum was performed by adding this mixture to the slides for 30 minutes where 
after primary antibody was added (different dilutions depending on antibody) followed by 
incubation overnight. 
 
The following day, the slides were washed and secondary antibody was added for 45 minutes. 
Slides were washed and an avidin-biotin complex (ABC) was used to biotinylate the 
secondary antibody. Horse radish peroxidase (HRP) was added in order to visualize the 
antibody staining in the following step. After 40 minutes of incubation, the slides were washed 
and developed with chromogen 3’ diaminobenzydine (DAB). 
 
Finally, the slides were washed and placed in haematoxylin for 30 seconds in order to obtain 
counterstaining. Following this, the slides were washed for 5 minutes in running water, 
dehydrated in increasing concentrations of ethanol and xylene, mounted with coverslips and 
visualized under a light microscope. 
 
 
3.3.4.1    Visual evaluation 
 
Slides were evaluated by two independent individuals simultaneously, either counting the 
number of CD8+ and CD4+ tumor infiltrating lymphocytes (TILs) or analyzing the expression 
and intensity of the CD44 staining.  
 
For CD4+ and CD8+ TILs, the evaluation was noted as: high, medium and low infiltration of 
TILs. The counted lymphocytes were those residing in in the tumor. These could however not 
be counted in areas close to veins and arteries since these cells might not have migrated into 
the tumor but instead just be passing by in the circulatory system. Staining of lymphocytes 
within the healthy tissue surrounding the tumor was used to determine the strength of positive 
staining. 
 
With regard to CD44 expression, the tumors were evaluated by the percentage of CD44 
positive cells and the intensity of staining. Staining intensity was evaluated as strong, weak or 
absent as compared to the surrounding normal tissue. Percentages were approximated based 
on the total amount of tumor present in each section and the percent of staining of the same. 
 
The p16 staining performed in our lab was determined as positive or negative. A sample was 
regarded as positive when tumor tissue showed successful staining of >70% of the tumor.174 
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3.3.5    Statistical analysis 
 
In all papers included in this thesis, statistical analysis was used to some extent. However the 
choice of statistical software varied.  
 
Two definitions with regards to patient survival are of great importance: 
 
Overall survival (OS) – follow up time for each patient was defined as time from diagnosis 
until death or in the case when patient was still alive after 3 years, they were considered 
censored at that time point. 
 
Disease free survival (DFS) – follow up time was defined as lack of disease recurrence. 
Patients that died of their disease without prior recurrence were excluded from calculations, 
since they were considered not cured. Time of death from other causes (and without 
recurrence) was also a point for censoring. 
 
 
Statistical methods: 
In paper III and V, a Chi2-test was used to in order to compare unordered categorical 
variables, such as e.g. gender. This test is usually applied when the sample is large. However, 
in smaller samples, usually defined as a group < 5, a two-tailed Fishers exact probability test 
can be used instead, as in paper I, III and IV. 
 
In paper V, an independent T-test was used to calculate differences in mean age between 
patient groups. 
 
In paper III-V, survival was measured in years/days from the date of diagnosis until a defined 
event or to 3 years after diagnosis. Overall survival (OS) was defined as time from diagnosis 
until death of any cause. Disease-free survival (DFS) was defined as time from diagnosis until 
relapse in disease. Patients who died before a prior recurrence were censored at day 0 / death 
date. The Kaplan-Meier estimate was used to estimate OS and DFS, followed by a log-rank 
test for differences in survival between groups, e.g patients with HPVDNA+ versus HPVDNA- 
tumors. 
 
Unadjusted and adjusted Hazard ratios (HR) were calculated with a Cox regressionfor data in 
Paper IV. This method investigates the effect of several variables upon the time a specified 
event happens, e.g. death by disease. This function will provide better estimates of survival 
probability and cumulative hazard ratios as compared to a Kaplan-Meier calculation, if the 
assumptions are met. This method was further used in Paper V, creating a univariate and a 
multivariate Cox regression model. 
 
The Wilcoxon-Mann-Whitney test (WMW) is generally a test for the comparison of two 
independent random samples. This was used in Paper IV to investigate differences in 
continuous and ordered categorical variables, e.g. counts of CD8+ cells. 
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Paper I also included calculations for HPV16 concordance between genital and oral samples. 
This was performed by calculating the Kappa statistic. This value gives a numerical rating of 
the degree of chance by which two values agree. A perfect agreement will give you a kappa 
value of 1 and an agreement occurring by chance gives a value of 0. 
 
In addition, in Paper II box-plot calculations were performed with R-statistical software 
(version 3.0.1), graphically investigating the differences in MFI in-between patients and 
healthy youth. 
 
Other software used were GraphPad Software for Paper III, SAS software (ver. 9.3, SAS 
Institute Inc., Cary, NC, USA) in Paper IV and SPSS (IBM SPSS Statistics, version 20, 
Stockholm, Sweden) in Paper V. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I. 
         Prevalence of oral human papillomavirus infection among youth, Sweden 
 
Aim: To investigate the prevalence of oral HPV infection at base line in young men and 
women attending a youth clinic in Stockholm 2009-2011 before the introduction of public 
HPV vaccination in Sweden. 
 
Study subjects, Methods and Results 
In all, 408 women and 82 men aged 15-23 years of age were included in the study contributing 
with mouthwash samples, and 180 women also donated cervical swabs. All samples were 
tested for 24 different mucosal HPV-types by the use of a Luminex-based multiplex assay. 
Seven oral samples and one cervical sample were excluded due to insufficient material. 
 
In total, 9.3% of the oral samples were HPV-positive with 9.2% among women and 9.8% 
among men. Cervical HPV infection was observed in 74.1% of the cases, and 64.9% of these 
were caused by HR-HPV types in the 174 women donating a cervical sample as well as an 
oral sample. HPV16 was the most common HR HPV-type, present in 2.9% of all oral samples 
and 37.9% of all cervical samples. Infections with more than one HPV type was frequent in 
the cervix and found in the majority of the cases, while only 16% of the HPV positive 
mouthwash samples presented more than one HPV type. Of note, in general the MFI values 
were much higher for HPV in cervical samples as compared to samples from the oral cavity.  
 
Oral and cervical samples from 174 women were paired and among the 24 women with an 
oral HPV infection, 22 of them also had a cervical HPV infection. Furthermore, there was 
HPV type concordance for 20 of 22 (90.9%) cases between the two sites.  
 
Notable was also that oral HPV infection was more common in women with cervical HPV 
infection (17.1%) compared to those without cervical HPV infection (4.4%).  
 
 
 
Table 3. HPV prevalence in mouthwash samples and cervical samples from youth, 
Stockholm, Sweden. Adapted from Du et al. 2012 
 
      No. (%) samples    . 
HPV-positive categories Oral Cervical 
Any HPV 45 (9.3) 129 (74.1) 
High risk-HPV 35 (7.2) 113 (64.9) 
HPV16 14 (2.9) 66 (37.9) 
HPV18 1 (0.2) 35 (14.49) 
Total no. samples 483 174 
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Discussion 
The main goal of this project was to investigate oral HPV prevalence of healthy in youth, 
before public HPV vaccination.  
 
With this aim in mind it could be argued that the cohort was biased. Firstly, the cohort may not 
be representative of average youth of the same age. Since the youth visiting the clinic were 
there to consult for birth control and sexually transmitted diseases (SDTs) and likely to have 
had more sex partners and hence be at greater risk of infection with any SDT. In addition, the 
size of the cohort included in the study was relatively limited since ~4000 women and 800 
men visit the clinic each year, but only 408 women and 82 men enrolled. Consequently, the 
actual test group had the potential to be larger and sampling could have been more evenly 
distributed during the time period whilst the study was ongoing and between women and men. 
In addition, the sampling frequency varied over time depending on the workload of the nurses 
at the clinic, and whether there were many patients visiting or if many nurses were on sick 
leave. In all these cases the nurses did not have time to ask visitors to contribute. The gender 
distribution is explainable since the female’s visitors outnumber the male visitors 5 times, a 
ratio which is reflected in our cohort where almost 500 women as compared to only 82 men 
contributed with samples. . Individuals whom are sexually active provide a good basis for 
sample collection and a youth clinic represents a very good place for collecting these types of 
samples. The probably higher oral HPV prevalence among this group is an advantage to 
establish the relative frequency of different HPV types and the possible effect of HPV 
vaccination on oral prevalence. 
 
The oral HPV prevalence observed, i.e. 9.3% in the whole cohort (9.2% in women and 9.8% 
in men), was somewhat higher but relatively comparable with other studies both in the US and 
other Western countries REF.175 Later studies of more population-based cohorts have shown a 
lower oral prevalence, both among youth and other age groups. The fact that 70% of the 
cervical infections were caused by HR-HPV types was similar to a previous study at this youth 
clinic and expected.81 Notably, HPV MFI signals, giving a semi-quantitative assessment of the 
copy number of HPV DNA in the samples, were lower in oral as compared to cervical 
samples and multiple cervical infections were more frequent as compared to multiple 
infections in the oral cavity. The lower HPV MFI signals obtained in oral samples as 
compared to oral samples could for partly be due to that in the oral cavity, the samples are 
diluted with saliva, which is produced in the magnitude of 0.5-1.5 liters/day.  
 
The 174 paired cervical and oral samples disclosed some interesting data. First of all, oral 
infection was more common in women with cervical infection (17.1%) compared to those 
without cervical infection (4.4%). Furthermore, of the 22 women with simultaneous oral and 
cervical infection there was a 90.9% HPV-type concordance, suggesting that they may have 
been acquired from the same partner.  
 
Conclusion: Oral HPV prevalence was 9.3% in youth and equal among women and men at 
a youth clinic in central Stockholm, before public HPV vaccination and oral infection was 
more common in women with, as compared to women without cervical HPV infection. 
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4.2 PAPER II. 
          Human papillomavirus prevalence is high in oral samples of patients with tonsillar and  
          base of tongue cancer 
 
Aim: To study if patients with HPVDNA+ TSCC and BOTSCC could be distinguished from 
patients with other HNSCC by HPVDNA testing mouthwash samples and/or tonsillar swabs. 
 
Patients, Methods and Results 
The study included 76 patients with suspected HNSCC, admitted to the Karolinska University 
Hospital for a diagnostic endoscopy. Definite diagnosis of HPV in the tumor biopsies was 
collected from patient journals, and compared to results from the non-invasive sampling by 
mouthwash or tonsillar swabs. As HNSCC free controls, 37 dental patients from the Dental 
School at Karolinska Institutet were included. 
 
Of the 76 patients with suspected HNSCC, 29 patients were diagnosed with TSCC and 18 
patients with BOTSCC, with 76% and 89% of the respective cases being HPVDNA+ according 
to the patient records. From patients with HPVDNA+ TSCC, 82% presented oral samples with 
HPV type concordance with the tumor biopsy, while the corresponding figure for HPVDNA+ 
BOTSCC was 50%. Of the remaining 29 patients, 19 presented HNSCC other than TSCC and 
BOTSCC and 10 had benign conditions such as tonsillitis or fungal infections, and of all these 
patients 4/29 (14%) had HPVDNA+ oral samples. 
 
The majority 27/32 (84%) of the HPVDNA+ oral samples were thus obtained from 26 patients 
with HPV type concordant TSCC or BOTSCC and in one case a patient with an unknown 
primary of the head and neck. HPV16 dominated in TSCC and BOTSCC and the MFI values 
were high, indicating a high viral load. More specifically, HPV16 MFI values in mouthwash 
samples from patients with TSCC and BOTSCC were generally higher compared to those in 
mouthwash samples from healthy youth. Figure 13 shows a boxplot for HPV16 MFI values of 
oral samples from patients with TSCC and BOTSCC as compared to those obtained from 
youth aged 15-23 years in Paper I (with an average MFI of around 250 and 20 respectively).  
The dental patients had an oral HPVDNA+ prevalence of 8%. This was similar to the prevalence 
reported among youth in Paper I (9.3%), but somewhat lower than observed in patients with 
HNSCC other than TSCC and BOTSCC and other conditions (14%). 
 
In addition, tonsillar swab samples from 60 patients: 22 TSCC, 15 BOTSCC and 25 from 
HNSCC other than TSCC and BOTSCC and benign conditions were sent and successfully 
evaluated with cytology at the Regina Elena National Tumor Institute and San Galliciano 
Institute of Dermatology. Clearly malignant cells were found in 7% (4/60) of the samples, 
whereas 33% (20/60) were classified as ASCUS (Atypical Squamous Cells of Undetermined 
Significance). Of those with clearly malignant cytology 3/4 were contributed by patients with 
TSCC, while the final sample was from a patient presenting with cancer of the mobile tongue. 
The 20 ASCUS samples were evenly distributed among the diagnoses, 7 TSCC and 6 BOTSC 
and 7 other HNSCC and benign conditions. Notable was that 50% of HPVDNA+ TSCC that 
could be evaluated had ASCUS or clearly malignant samples. 
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Figure 13. Boxplot showing MFI-values in HPV16 positive mouth wash samples obtained 
from healthy youth and patients with HPV16 positive TSCC and BOTSCC.   
 
 
Discussion  
The purpose of this project was to investigate to which extent patients with HPVDNA+ TSCC 
and BOTSCC had HPVDNA+ oral samples and could be distinguished from other HNSCC 
patients.  Testing for HPVDNA in oral samples from 76 patients undergoing an endoscopic 
diagnostic biopsy for the suspicion of a HNSCC, it was shown that 89% of HPVDNA+ oral 
samples were from patients with HPVDNA+ TSCC and BOTSCC or an HPVDNA+ unknown 
primary. Furthermore, if limiting the analysis to HPV16DNA+ samples with MFI signal >200, 
100% of the HPV16DNA+ oral samples were derived from TSCC, BOTSCC or an unknown 
primary of the head and neck. Thus an HPVDNA+ oral sample, especially HPV16DNA+ with a 
relatively high viral load, is very likely belonging to a patient with an HPVDNA+ TSCC or 
BOTSCC. 
 
Nevertheless, there were HPVDNA- oral samples from patients with HPVDNA+ tumors. The 
overall the reliability of the method was higher for HPVDNA+ TSCC as compared to HPVDNA+ 
BOTSCC, where 82% as compared to 50% respectively of the oral samples were HPVDNA+. 
The most plausible reason for this higher sensitivity is that when sampling tonsillar swabs and 
mouthwash samples one most likely enrich for cells from the tonsills rather than from the base 
of tongue, which is further down in the oral cavity. It is possible that by taking swabs from the 
base of tongue one could increase the number of HPVDNA+ oral samples obtained for patients 
with BOTSCC. It was also noted that oral samples from HPV33DNA+ TSCC and BOTSCC 
were more often HPV33DNA-, probably due to a lower sensitivity for HPV33 in the assay. 
 
In addition, 14% of patients with other HNSCC or benign conditions and 8% of the dental 
patients also had HPVDNA+ oral samples, indicating that not only patients with TSCC or 
BOTSCC may have positive oral samples. This was not unexpected since oral HPVDNA 
prevalence of both these cohorts was fairly similar to that obtained among youth (9.3%) at the 
youth clinic in Paper I. However, none of these patients had HPV16 with MFI >200.  
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The above finding prompted us to compare MFI values from patients with HPVDNA+ TSCC 
and BOTSCC with those obtained among youth at the youth clinic. Here we found an obvious 
difference since HPV16 MFI values in youth had a median MFI of 20 as compared to a 
median MFI of 250 among patients with HPVDNA+ TSCC and BOTSCC.  
 
Finally, cytopathological data from tonsillar swabs collected from 60 patients with sufficient 
material displayed varying results. Clearly malignant cytology was not obtained for most 
patients this way. Material was inadequate or not available for 7 of the 22 patients with 
HPVDNA+ TSCC and among the remaining 15 samples, seven showed malignant cytology or 
ASCUS (47%). The sensitivity for BOTSCC was much weaker, which was not unexpected, 
and very likely the sensitivity would have been improved if a swab had been taken from the 
base of the tongue instead. 
 
 
Conclusions 
 
• HPVDNA+ oral samples were mainly derived from patients with HPVDNA+ TSCC and 
BOTSCC, with somewhat lower sensitivity in the latter group.  
 
• When comparing HPV16 MFI values in mouthwashes from patients with HPV16DNA+ 
TSCC and BOTSCC and youth there were considerable differences i.e. with average 
MFI median values of 200 and 20 respectively. 
 
• Based on our findings in Papers I and II, we conclude that individuals with 
HPV16DNA+ oral samples with relatively high HPV viral loads should be checked for 
the possible presence of an HPVDNA+ TSCC or BOTSCC. 
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4.3 PAPER III. 
 
Human papillomavirus (HPV) 16 E6 variants in tonsillar cancer in comparison to those 
in cervical cancer in Stockholm, Sweden 
 
Aim: To investigate HPV16 E6 variants in tonsillar cancer (TSCC) as compared to those in 
cervical cancer (CC) and cervical samples (CS) of healthy young women. 
 
Patients, Material, Methods and Results 
FFPE material of HPV-positive TSCC was randomly selected from a cohort of 290 patients 
with TSCC diagnosed in Stockholm between 2000 and 2007 (see Figure 14). CC samples 
were selected from a cohort of patients diagnosed between 2003 and 2008. Totally 55 TSCC 
and 52 CC samples were chosen for the initial comparison, later an additional 53 TSCC from 
the original TSCC cohort were included for validation. Furthermore, 51 CS samples were 
chosen from a previous study.81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Flow chart of patients with TSCC included in the study 
 
Sequencing for HPV16 E6 was first performed for an initial group of samples (55 TSCC, 52 
CC and 51 CS). The most common variant found in all groups was the L83V, which was 
observed in 45% of the TSCC, 31% of the CC and 29% of the CS. Notably, the otherwise rare 
mutation R10G was rather common (22%) in the TSCC samples, rare in the CS samples (4%) 
and completely lacking in the CC samples. The differences were found to be significant 
between both TSCC and CC (p=0.0003) as well as for TSCC compared to CS (p=0.009). 
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When analyzing the frequency of these two variants in 53 additional HPV16 positive TSCC 
samples a similar result was achieved with 17% R10G and 34% L83V positive samples. No 
significant difference was observed when summarizing the two groups of TSCC, and the total 
frequencies obtained for R10G and L83V were 19% and 40%, respectively.  
 
Notably, the majority of samples containing R10G also harbored L83V. Other mutations were 
detected in all sample groups, but these were however uncommon in comparison and of these 
the two most common ones (Q14H and H78Y) were present in only 4% of the CC and CS and 
7% of the TSCC cases.  
 
When considering HPV16E6 variants with different geographic origins the European 
prototype was found in 38% of the TSCC, 65% of the CC and 59% in the CS. If one includes 
samples harboring the European variant with minor differences (such as R10G and L83), the 
percentage increased to >90% for all sample types. Other prototypes of HPV16E6 such as 
African-1 and 2, East Asian, Asian American and North American were rare and only 
observed in a few samples. 
 
No significant differences were observed among patients with TSCC with regard to TNM-
status, stage or 3-year disease-free survival (DFS) when comparing the ones with or without 
the R10G and L83V.  
 
Discussion 
In this study, the aim was to investigate whether there were any differences between 
HPV16E6 variants observed in TSCC, CC and CS, indicating that there could be differences 
in the affinity or ability of different variants to survive at different locations. 
 
The common L83V found in 45% of the TSCC, 31% of the CC and 29% of the CS implied 
that there were no major differences with regard to the location of this variant, although it has 
often been suggested to be more prone to cause cervical cancer.176 Furthermore, the similar 
frequencies of L83V in CC and CS samples, argues against this hypothesis. Notable was that 
the R10G variant, which is in general very rare, was present in 19% of the TSCC samples, 
while it was only present in 4% of the CS samples and completely absent in the CC samples. 
This suggests that this variant may be more able to adapt itself in the oral cavity or 
alternatively that it is more prone to cause cancer in this region.  
 
A limitation of this study was that no oral samples from healthy individuals were included. 
This was mainly due to that we only had 12 HPV16 positive oral samples from the study on 
youth from the youth clinic and that these samples had a very low HPV signal making 
sequencing difficult. However, in future studies it may be valuable to embark on such a task. It 
would namely be useful to know, whether this variant is more common in the oral cavity and 
therefore present in TSCC or if it is more carcinogenic as such as compared to other HPV16 
variants. 
 
Presence of different variants was also correlated to clinical outcome in TSCC, but no 
significant differences were observed. However, with the limited number of patients and the 
high survival in this patient group such differences are difficult to detect. 
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Conclusions 
 
• L83V was fairly common in TSCC, CC and CS and was distributed equally between 
the latter two and not enriched for in CC 
 
• The rare mutant R10G was found in TSCC but not in CC, while in CS it was found in 
4% of the cases. From the presently obtained data it cannot be determined whether 
R10G was selected against in CC, instead further studies are needed.  
 
• Finally, none of the above variants showed any significant impact on patient clinical 
outcome 
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4.4 PAPER IV. 
 
CD8+ and CD4+ tumor infiltrating lymphocytes in relation to human papillomavirus 
status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma 
 
Aim: To estimate the numbers of CD8+ and CD4+ tumor infiltrating lymphocytes (TILs) in 
TSCC and BOTSCC and in combination with HPV-status in relation to clinical outcome.  
 
Patients, Materials, Methods and Results 
For this study, 280 FFPE tumor biopsies were obtained from a cohort of patients diagnosed 
with TSCC and BOTSCC and treated with curative intent between 2000 and 2007. All 
samples had been previously tested for presence of HPV DNA and expression of p16INK4a 
(p16). Immunohistochemistry was used to stain CD8+ and CD4+ TILs, and the number of TILs 
was estimated by two independent researchers.   
 
In all, 79% of the tumors were HPV DNA positive (HPVDNA+) with HPV16 being present in 
94% of the cases. The remaining 6% were positive for either HPV33, 35, 56, 58 or 59. 
Patients with HPVDNA+ TSCC were in general younger than patients with HPV DNA negative 
(HPVDNA-) tumors and had a lower T-stage. Patients with HPVDNA+ BOTSCC had a higher 
nodal stage and clinical stage compared to those with HPVDNA- tumors. No significant 
difference in gender prevalence depending on HPV DNA status was observed. p16 
overexpression was observed in 82% of the HPVDNA+ tumors and in 8% of the HPVDNA- ones 
(p<0.001) with a slightly higher prevalence among patients with TSCC.  
 
TILs can be regarded as important for the immune response and the number of CD8+ TILs 
has been previously shown to be important for clinical outcome in other tumors and 
therefore of interest to study also here.177  
 
CD8+ TILs could be evaluated in 275/280 (98%) of the tumors and CD4+ TILs in 268/280 
(96%) of the cases. Significantly higher numbers of CD8+ TILs as well as CD4+ TILs cells 
were found in the HPVDNA+ group of tumors.  
 
Notably, high CD8+ TIL, but not CD4+ TIL counts were found to be a favorable prognostic 
factor among patients with HPVDNA+ as well as HPVDNA+/p16-positive tumors. This was 
especially obvious after dividing the patients into 4 quartiles, observing 3-year overall 
survival (OS) and disease free survival (DFS), which was significantly better for all but the 
group with the lowest CD8+ TIL counts (Figure 15). For patients with HPVDNA- tumors there 
was a similar tendency, however statistical significance was obtained only for OS and for 
the quartile with the highest CD8+ TIL counts.    
 
In contrast, high CD4+ TIL counts were not found to affect clinical outcome in patients with 
HPVDNA+ or HPVDNA+/p16 positive tumors. Nevertheless, a tendency of better survival for 
patients with HPVDNA- and HPVDNA-/p16 negative tumors was observed.   
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Figure 15. Kaplan-Meier curves displaying OS and DFS for HPVDNA+ TSCC (A and B 
respectively) and HPVDNA+/p16-positive TSCC (C and D respectively), with data stratified for 
CD8+ TIL counts divided into 4 quartiles. 
 
Discussion 
The aim of this study (and Paper V as follows below) was to investigate the use of additional 
biomarkers in combination with HPV-status in TSCC and BOTSCC to better predict clinical 
outcome and to potentially better select patients with HPVDNA+ tumors for randomized trials 
with less aggressive therapy than that given today.   
 
Both Paper IV and V make use of the same cohort i.e. patients diagnosed with TSCC and 
BOTSCC 2000-2007 at the Karolinska University Hospital. In this study 280 biopsies were 
available as compared to 290 biopsies in Paper V. The reason for the discrepancy is due to that 
it was not always possible to obtain enough material in order to stain for all markers.  
 
In this study 79% of the TSCC and BOTSCC samples were HPV DNA positive, with 
dominance of HPV16. In all 82% of HPVDNA+ cases were also p16 positive, while only 8% of 
the HPVDNA- tumors were p16 positive. Since being HPVDNA+/p16 positive is regarded as 
almost equivalent to being HPV E6/E7 mRNA positive, i.e. the golden standard for a HPV 
driven tumor,73 clinical outcome was investigated for this group too.  
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In general, HPVDNA+ tumors displayed higher counts of CD8+ TILs than HPVDNA- tumors. 
Therefore, when making comparisons of the importance of CD8+ TILs, the two groups were 
evaluated separately. This division may explain why the three highest quartiles for HPVDNA+ 
and HPVDNA+/p16 positive groups all were correlated to a better clinical outcome. 
Accordingly, in order for patients with HPVDNA- cancer patient group to benefit from high 
CD8+ TIL counts, they had to belong to the quartile with the highest count of infiltrating cells. 
 
Infiltration with CD4+ TILs could not be linked to clinical outcome or survival for patients 
with HPVDNA+ tumors, although there was a tendency of better survival for patients with 
HPVDNA- and HPVDNA-/p16-negative tumors with high CD4+ TIL counts. This issue would be 
interesting to unravel and followed up in later studies in larger cohorts of HPVDNA- cancer if 
possible. On the other hand it is unlikely that treatment will be de-escalated for this patient 
group within the near future and therefore such a study would not be a first priority. 
 
 
Conclusions 
 
• Patients with HPVDNA+ and HPVDNA+/p16 positive TSCC and BOTSCC which belong 
to the three highest quartiles of CD8+ TIL counts have a significantly better clinical 
outcome than those belonging to the lowest quartile 
 
• For patients with HPVDNA- cancer only those with the highest quartile of CD8+ TIL 
counts have an increased survival 
 
• CD8+ TIL counts have the potential to be used as a biomarker to predict clinical 
outcome in HPVDNA+ and HPVDNA+/p16 positive TSCC and BOTSCC 
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4.5 PAPER V. 
Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in 
oropharyngeal squamous cell carcinoma indicates a very high survival 
 
 
Aim: To investigate whether CD44 could be used as a potential biomarker to identify patients 
with HPV DNA positive (HPVDNA+) or HPV DNA+/p16 positive TSCC and BOTSCC with a 
better clinical outcome. 
 
Patients, Material and Results 
In all, 290 patients with TSCC or BOTSCC diagnosed between 2000 and 2007 and with 
available tumor biopsies were included in the study. Totally, 78% of the tumors were HPV 
DNA positive with HPV16 accounting for 94% of the cases. Out of the HPVDNA+ cases 90% 
were also p16 positive, the same was true for 8% of the HPVDNA- cases. Clinical outcome was 
evaluated for patients with HPVDNA+ tumors and for those with HPVDNA+/p16-positive tumors, 
where the latter are regarded as more likely to have an active HPV infection. Clinical outcome 
was also evaluated for patients with HPVDNA-/p16 negative tumors. Patients with HPVDNA+ or 
HPVDNA+/p16-positive tumors were younger at diagnosis, had smaller tumors, and higher level 
of nodal disease and stage than those with HPVDNA- cancer. No significant differences were 
observed with regard to gender, presence of metastasis or tumor localization. 
 
A sample was regarded as CD44-positive when >25% of the cells displayed CD44 staining. 
Among the 290 tumors included, 92% expressed CD44 with a majority displaying strong 
intensity staining (53%), while 26% had intermediate staining and 21% showed weak staining. 
Patients with CD44-positive tumors showed higher differentiation and had larger tumors to a 
significantly higher degree than those considered as CD44-negative. However, CD44-
positivity alone was not correlated to clinical outcome irrespective of HPV status and was 
therefore not pursued further.  
 
The impact of CD44 intensity staining was therefore investigated. This was done by dividing 
the samples into two groups, absent/weak- and medium/strong-CD44 intensity staining. It was 
then shown that HPVDNA- samples more often expressed medium/strong intensity staining, as 
compared to HPVDNA+ tumors (91% vs. 65%, p<0.001).  
 
Furthermore, when considering CD44-intensity staining in relation to DFS and OS, it was 
noted that an absent/weak CD44 intensity staining lead to a better 3-year DFS and OS for all 
tumors, irrespective of HPV status as compared to those expressing medium/strong CD44 
intensity staining. A univariate analysis and multivariate analysis was performed (Table 3) 
showing that patients with HPVDNA+ tumors had a better clinical outcome than those with 
HPVDNA- tumors.  Furthermore, patients with tumors with absent/weak CD44 intensity 
staining had a significantly better DFS and OS than those with medium/strong CD44 
intensity staining. 
 
Investigating HPVDNA+ and HPVDNA- (Table 3, Figure 16) and HPVDNA+/p16 positive and 
HPVDNA-/p16 negative tumors (Figure 17) performing a Kaplan-Meier analysis also yielded 
useful information.  
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Patients with HPVDNA+ tumors and absent/weak CD44 staining were again found to have a 
better 3-year DFS and 3-year OS than those with tumors with medium/strong CD44 intensity 
staining, while the difference was not significant for the smaller HPVDNA- group (Table 3).  
 
For patients with HPVDNA+/p16 positive with absent/weak CD44 intensity staining there was a 
trend of a better 3-year DFS and 3-year OS (Figure 16), as compared to those with tumors 
with medium strong CD44 intensity staining, but the values did not reach statistical 
significance. For patients with HPVDNA-/p16 negative, no additional significant increase in 3-
year DFS or 3-year OS was recorded in the group with absent/weak CD44 intensity staining as 
compared to that with medium/strong intensity staining (Table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Disease free survival in patients with HPVDNA+/p16 positive tumors in relation to 
CD44 intensity staining of their tumors. 
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Discussion 
The aim of this study was to investigate the use of CD44 as a biomarker in combination with 
HPV-status in TSCC and BOTSCC to better predict clinical outcome and to evaluate the 
future use of personalized therapy.  
 
HPV positive status was examined as HPVDNA+, or HPVDNA+/p16 positive, where the latter is 
regarded to be close to the golden standard and indicative of an active HPV infection. 
HPVDNA- status was examined as HPVDNA- or HPVDNA-/p16 negative. 
 
Irrespective of HPV status, most tumors stained positive for CD44. However, CD44 positivity 
as such did not have an impact on clinical outcome. However, when examining differences in 
CD44 intensity staining, a new picture emerged. It was observed that patients with tumors 
with absent/weak intensity staining had a better clinical outcome than those with 
medium/strong CD44 intensity staining. This marker was hence further pursued. 
 
When investigatingCD44 intensity staining further, it was found that patients with HPVDNA+ 
tumors with absent/weak CD44 intensity staining had a significantly better 3-year DFS and 3-
year OS than patients with medium/strong CD44 intensity staining. For patients with HPVDNA- 
tumors the same trend was observed, however the number of patients was limited and 
statistical significance was not obtained. For patients with HPVDNA+/p16 positive tumors with 
absent/weak CD44 intensity staining there was a trend for a better 3-year DFS and 3-year OS, 
but this trend did not reach statistical significance. Thus there was a difference with regard to 
the use of CD44 intensity staining as compared to CD8+ TILs in this group of patients 
suggesting that CD8 TIL counts may be a better biomarker for clinical outcome in patients 
with HPVDNA+/p16 positive tumors (see Paper IV). 
 
Moreover, when comparing the HPVDNA+ group to the HPVDNA+/p16 positive group one can 
observe a cumulative survival increase both for DFS and OS in the group with CD44 
medium/strong intensity staining in the latter group. 
 
This was most likely due to exclusion of all patients with the HPVDNA+/p16 negative samples, 
since these patients do worse as compared to patients with HPVDNA+/p16 positive samples. We 
hypothesize that this in part could explain why a statistical significant difference was not 
observed between patients with absent/weak vs. medium/strong HPVDNA+/p16 positive 
tumors. 
 
Conclusions 
 
• Among patients with TSCC and BOTSCC, and patients with HPVDNA+ TSCC and 
BOTSCC absent/weak as compared to medium/ strong CD44 intensity staining 
indicated a significantly better 3-year DFS and OS 
 
• In patients with HPVDNA+/p16 positive and HPVDNA- TSCC and BOTSCC absent/weak 
as compared to medium/ strong CD44 intensity indicated a trend for better 3-year DFS 
and OS. For this purpose the impact of CD44 intensity as a predictive marker needs to 
be investigated further 
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5 CONCLUSIONS 
 
 
 
• Oral HPV infection was relatively common among youth attending a youth clinic in 
Stockholm 2009-2011, before public HPV vaccination as compared to other studied 
populations in Europe and the U.S. (Paper I) 
 
• Oral HPV infection was more common in women with genital infection and there was 
HPV type concordance between the oral and cervical sites (Paper I) 
 
• When testing patients with suspected HNSCC, HPVDNA+ oral samples were mainly 
derived from patients with HPVDNA+ TSCC and BOTSCC (Paper II)  
 
• The relative HPV viral load (Median Fluorescent Intensity) was significantly higher in 
mouthwash samples of patients with HPVDNA+ TSCC and BOTSCC as compared to 
similar samples from healthy youth. This makes non-invasive mouthwash or other oral 
samples potentially a basis for developing routine testing for HPVDNA+ TSCC and 
BOTSCC (Paper I and II) 
 
• The HPV16E6 L83V variant was common in TSCC, CC and CS, while the rare 
HPV16E6 R10G variant was present in a proportion of TSCC, but absent in CC and 
only sporadic in CS samples (Paper III) 
 
• Neither the HPV16E6 common L83V nor the rare R10G variants had any significant 
impact on clinical outcome. However, it is possible that the R10G variant is more 
adapted to infecting the tonsils or that is more prone to cause TSCC than the European 
prototype. Hence further investigation of this variant can be of interest (Paper III) 
 
• Both high CD8+ TIL infiltration and absent/weak CD44 intensity staining appeared to 
be promising predictive markers for patients with HPVDNA+ TSCC and BOTSCC. 
However for patients with HPVDNA+/p16 positive TSCC and BOTSCC only CD8+ 
TILs retained statistical significance, indicating that this marker was the better one of 
the two (Paper IV and V) 
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6 FUTURE PERSPECTIVES 
 
In Paper I we monitored oral and cervical HPV-prevalence in young sexually active 
individuals prior to public vaccination and found high HPV-prevalence for both the cervical 
and oral tracts. However, studies that we have performed on HPV-prevalence need to be 
followed up since public HPV vaccination has been initiated from 2012. Our hope is that 
infection with HPV16 and 18 will decrease (together with HPV6, HPV11 and other types 
affected by cross-protection), both in the anogential area and in the oral cavity. This decrease 
is likely to contribute to a decreased number of cervical cancers but also to a decrease in HPV 
related cancers of the head and neck among both men and women.   
 
 
The insight that patients with HPVDNA+ TSCC and BOTSCC have higher viral load in the oral 
cavity, as compared to HPVDNA+ healthy youth, gives new possibilities for future research. 
Furthermore, the finding that patient with HPVDNA- HNSCC usually doesn’t show oral 
positivity adds to this potential. One should aim to develop an easy-to-use non-invasive test, 
which can be utilized by health care staff to give a specific and quick answer. This test should 
provide information whether there is an ongoing HPV infection and whether the patient should 
go through further examination as to rule out HPVDNA+ TSCC or BOTSCC from the 
diagnosis. 
 
 
Studies on different variants of HPV16E6 are of importance, especially since we found that 
the R10G variant is more common in TSCC as compared to in CC and in CS. This was an 
observation in patients from the Stockholm County and whether this is the case also in 
samples from other areas needs to be further investigated. In addition, since no significant 
impact on clinical outcome was observed, possibly due to the limited number of samples 
examined, further investigation in larger cohorts could be considered. 
 
 
Considering the results from Paper IV and V, further investigation of biomarkers is of great 
importance. If one had a strong panel of biomarkers, with high accuracy identifying patients 
with HPVDNA+ TSCC and BOTSCC with better clinical outcome, then personalized medicine 
would not be science fiction. One could then investigate the potential benefit of deescalated 
treatment. However, it is crucial to validate the beneficial effects of high CD8+ TILs and 
absent/weak CD44 intensity staining in larger groups of patients, before attempting to use 
them to perform randomized trials with de-escalated therapy. 
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